|
G |
Atm |
ATM serine/threonine kinase |
increases phosphorylation |
ISO |
Flavanones results in increased phosphorylation of ATM protein |
CTD |
PMID:21616090 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases phosphorylation |
ISO |
Flavanones results in decreased phosphorylation of ATR protein |
CTD |
PMID:21616090 |
|
NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Flavanones results in increased expression of BAX protein |
CTD |
PMID:25446852 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Flavanones results in decreased expression of BCL2 protein |
CTD |
PMID:25446852 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp2 |
caspase 2 |
increases cleavage multiple interactions |
ISO |
Flavanones results in increased cleavage of CASP2 protein U 0126 promotes the reaction [Flavanones results in increased cleavage of CASP2 protein] |
CTD |
PMID:21616090 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
Flavanones results in increased cleavage of CASP3 protein |
CTD |
PMID:25446852 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases cleavage |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; CDKN1A gene mutant form promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; PI103 promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; TP53 gene mutant form promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; U 0126 promotes the reaction [Flavanones results in increased cleavage of CASP7 protein] |
CTD |
PMID:21616090 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccna1 |
cyclin A1 |
decreases expression |
ISO |
Flavanones results in decreased expression of CCNA1 protein |
CTD |
PMID:21616090 |
|
NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Flavanones results in decreased expression of CCNB1 protein |
CTD |
PMID:21616090 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Flavanones results in decreased expression of CCND1 protein |
CTD |
PMID:21616090 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Flavanones results in decreased expression of CCNE1 protein |
CTD |
PMID:21616090 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression decreases response to substance |
ISO |
CDKN1A gene mutant form promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; CDKN1A gene mutant form promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein] Flavanones results in increased expression of CDKN1A protein CDKN1A protein results in decreased susceptibility to Flavanones |
CTD |
PMID:21616090 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation |
ISO |
Flavanones results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:21616090 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Flavanones results in decreased activity of CYP19A1 protein |
CTD |
PMID:17910019 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases phosphorylation |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein]; CDKN1A gene mutant form promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein]; PI103 promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein]; TP53 gene mutant form promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein]; U 0126 promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21616090 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Flavanones inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] Flavanones results in decreased expression of HIF1A protein |
CTD |
PMID:25446852 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Flavanones results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:21616090 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Flavanones results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21616090 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases phosphorylation |
ISO |
Flavanones results in increased phosphorylation of MDM2 protein |
CTD |
PMID:21616090 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases phosphorylation |
ISO |
Flavanones inhibits the reaction [cobaltous chloride results in increased phosphorylation of MTOR protein] Flavanones results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25446852 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
3-methyladenine promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Flavanones results in increased cleavage of PARP1 protein]; U 0126 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein] |
CTD |
PMID:21616090 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
Flavanones inhibits the reaction [cobaltous chloride results in increased phosphorylation of RPS6KB1 protein] Flavanones results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:25446852 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tp53 |
tumor protein p53 |
increases expression decreases response to substance multiple interactions |
ISO |
Flavanones results in increased expression of TP53 protein TP53 protein results in decreased susceptibility to Flavanones TP53 gene mutant form promotes the reaction [Flavanones results in increased cleavage of CASP7 protein]; TP53 gene mutant form promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21616090 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO |
Flavanones inhibits the reaction [cobaltous chloride results in increased expression of VEGFA protein] Flavanones results in decreased expression of VEGFA protein |
CTD |
PMID:25446852 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21871475 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21871475 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK1 protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK3 protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PDGFRB protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:21871475 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
EXP |
ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PDGFRB protein] |
CTD |
PMID:21871475 |
|
NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:21871475 |
|
NCBI chr 3:169,805,299...169,836,040
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Sphk1 |
sphingosine kinase 1 |
decreases expression decreases activity |
ISO |
ampelopsin results in decreased expression of SPHK1 protein ampelopsin results in decreased activity of SPHK1 protein |
CTD |
PMID:22251058 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:101,758,711...101,764,240
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
taxifolin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases activity |
ISO |
taxifolin inhibits the reaction [ABCC1 protein affects the export of S-(2,4-dinitrophenyl)glutathione] taxifolin results in decreased activity of ABCC1 protein |
CTD |
PMID:15041478 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Rotenone results in decreased activity of ACHE protein] |
CTD |
PMID:35187747 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions |
ISO |
taxifolin binds to and results in increased activity of ADIPOR2 protein |
CTD |
PMID:23691032 |
|
NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Afp |
alpha-fetoprotein |
affects binding multiple interactions |
EXP |
taxifolin binds to AFP protein alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]] |
CTD |
PMID:23013281 PMID:25349334 PMID:33840231 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
taxifolin results in decreased expression of AGT protein modified form |
CTD |
PMID:24269735 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of CYP1A1 mRNA]; AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:29584932 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:32828744 PMID:35465754 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
ISO |
taxifolin results in increased expression of APOA1 protein |
CTD |
PMID:11108730 |
|
NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
decreases secretion decreases expression |
ISO |
taxifolin results in decreased secretion of APOB protein taxifolin results in decreased expression of APOB protein |
CTD |
PMID:11108730 PMID:15380446 |
|
NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of BCL2 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]] |
CTD |
PMID:32525071 PMID:35465754 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of BECN1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of BECN1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]] |
CTD |
PMID:33840231 PMID:33882723 PMID:35465754 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
decreases activity multiple interactions |
EXP |
taxifolin results in decreased activity of CASP3 protein alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; taxifolin inhibits the reaction [Colistin results in increased activity of CASP3 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased activity of CASP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]] |
CTD |
PMID:24269735 PMID:32828744 PMID:33840231 PMID:33882723 PMID:35465754 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases activity multiple interactions |
EXP |
taxifolin results in decreased activity of CASP9 protein alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]] |
CTD |
PMID:24269735 PMID:33840231 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP ISO |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]; taxifolin analog inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; taxifolin inhibits the reaction [Acetic Acid results in increased activity of CAT protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CAT mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CAT mRNA]; taxifolin inhibits the reaction [Rotenone results in decreased activity of CAT protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]] taxifolin results in decreased activity of CAT protein taxifolin inhibits the reaction [Hydrogen Peroxide results in increased activity of CAT protein] |
CTD |
PMID:30372826 PMID:32525071 PMID:33741339 PMID:35187747 PMID:35465754 PMID:36198370 PMID:38574953 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna1 |
cyclin A1 |
decreases expression |
ISO |
taxifolin results in decreased expression of CCNA1 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
taxifolin results in decreased expression of CDC25A mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
taxifolin analog inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
taxifolin affects the localization of CYCS protein [taxifolin co-treated with dapagliflozin] inhibits the reaction [Colistin results in increased expression of CYCS protein]; taxifolin inhibits the reaction [Colistin results in increased expression of CYCS protein] |
CTD |
PMID:24269735 PMID:33882723 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CYP11A1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CYP11A1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CYP11A1 protein] |
CTD |
PMID:32525071 PMID:36198370 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
taxifolin results in increased expression of CYP1A1 mRNA; taxifolin results in increased expression of CYP1A1 protein AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:22422552 PMID:29584932 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
ISO |
taxifolin results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dcc |
DCC netrin 1 receptor |
increases expression |
ISO |
taxifolin results in increased expression of DCC mRNA |
CTD |
PMID:17541156 |
|
NCBI chr18:67,144,272...68,248,159
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
taxifolin results in decreased expression of EGF mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
decreases expression |
ISO |
taxifolin results in decreased expression of FGF18 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr10:18,210,240...18,241,929
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf3 |
fibroblast growth factor 3 |
decreases expression |
ISO |
taxifolin results in decreased expression of FGF3 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 1:209,430,457...209,434,832
Ensembl chr 1:200,001,261...200,005,187
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein] |
CTD |
PMID:32828744 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]] |
CTD |
PMID:35465754 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gas6 |
growth arrest specific 6 |
increases expression |
ISO |
taxifolin results in increased expression of GAS6 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr16:82,747,676...82,778,090
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
taxifolin results in increased expression of GDF15 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Rotenone results in decreased activity of GLUL protein] |
CTD |
PMID:35187747 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]] |
CTD |
PMID:32828744 PMID:33840231 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of GPX1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of GPX1 protein] |
CTD |
PMID:32525071 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]; taxifolin inhibits the reaction [Colistin results in decreased expression of GSR protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of GSR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]] |
CTD |
PMID:33882723 PMID:35465754 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
taxifolin results in increased expression of GSTM1 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
taxifolin results in increased expression of HMOX1 protein Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]] Chlorpyrifos inhibits the reaction [taxifolin results in decreased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:31152760 PMID:35465754 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of HSD17B3 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of HSD17B3 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD17B3 protein] |
CTD |
PMID:32525071 PMID:36198370 |
|
NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]] |
CTD |
PMID:35465754 PMID:36198370 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 mRNA]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12044887 PMID:19103272 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
taxifolin inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of STAT1 protein]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 mRNA]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; taxifolin inhibits the reaction [IFNG protein results in increased phosphorylation of MAPK8 protein] taxifolin inhibits the reaction [Chlorpyrifos results in increased secretion of IFNG protein] |
CTD |
PMID:12044887 PMID:19103272 PMID:31152760 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Rotenone results in increased expression of IKBKG mRNA] |
CTD |
PMID:35187747 |
|
NCBI chr X:157,358,279...157,397,563
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Colistin results in increased expression of IL15 protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of IL15 protein]] |
CTD |
PMID:33882723 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]] |
CTD |
PMID:33840231 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein]; taxifolin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] taxifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein] |
CTD |
PMID:32828744 PMID:35187747 PMID:38574953 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] taxifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein] |
CTD |
PMID:32828744 PMID:38574953 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of INSL3 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of INSL3 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSL3 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSL3 protein] |
CTD |
PMID:32525071 PMID:36198370 |
|
NCBI chr16:18,432,668...18,434,539
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
taxifolin results in decreased expression of JUN mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO EXP |
taxifolin inhibits the reaction [IFNG protein results in increased phosphorylation of MAPK8 protein] taxifolin inhibits the reaction [Colistin results in increased activity of MAPK8 protein] |
CTD |
PMID:12044887 PMID:33882723 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; taxifolin inhibits the reaction [Rotenone results in increased activity of MPO protein] |
CTD |
PMID:33741339 PMID:35187747 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]; taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases activity |
ISO |
taxifolin results in decreased activity of MTTP protein |
CTD |
PMID:15380446 |
|
NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions decreases expression |
ISO EXP |
taxifolin results in increased expression of NFE2L2 protein alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]; taxifolin inhibits the reaction [Colistin results in decreased expression of NFE2L2 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]] taxifolin results in decreased expression of NFE2L2 protein Chlorpyrifos inhibits the reaction [taxifolin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:16799064 PMID:31152760 PMID:33840231 PMID:33882723 PMID:35465754 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Rotenone results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35187747 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Colistin results in decreased expression of NGF protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of NGF protein]] |
CTD |
PMID:33882723 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression |
ISO |
taxifolin results in increased activity of NQO1 protein taxifolin results in increased expression of NQO1 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Oga |
O-GlcNAcase |
multiple interactions |
EXP |
[taxifolin co-treated with dapagliflozin] inhibits the reaction [Colistin results in increased activity of OGA protein]; taxifolin inhibits the reaction [Colistin results in increased activity of OGA protein] |
CTD |
PMID:33882723 |
|
NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:244,598,292...244,634,359
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein |
CTD |
PMID:32828744 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
taxifolin results in decreased expression of PDGFB mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
EXP |
taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein] |
CTD |
PMID:32828744 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]] |
CTD |
PMID:33840231 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases phosphorylation |
ISO |
taxifolin results in increased phosphorylation of PPARA protein |
CTD |
PMID:23691032 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of PPARGC1A protein] |
CTD |
PMID:32525071 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases phosphorylation |
ISO |
taxifolin results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:23691032 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
decreases phosphorylation |
ISO |
taxifolin results in decreased phosphorylation of PRKAA2 protein |
CTD |
PMID:23691032 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
taxifolin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rasa1 |
RAS p21 protein activator 1 |
decreases expression |
ISO |
taxifolin results in decreased expression of RASA1 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:15,857,980...15,940,854
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[alogliptin co-treated with taxifolin] inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of RELA protein]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of RELA protein]; taxifolin inhibits the reaction [Colistin results in increased expression of RELA protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of RELA protein]] |
CTD |
PMID:33840231 PMID:33882723 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SCARB1 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SCARB1 protein] |
CTD |
PMID:36198370 |
|
NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SIRT1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 protein] |
CTD |
PMID:32525071 PMID:36198370 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD1 protein] |
CTD |
PMID:32525071 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD2 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 mRNA] |
CTD |
PMID:32525071 PMID:36198370 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOX9 mRNA] |
CTD |
PMID:32525071 |
|
NCBI chr10:98,305,744...98,311,250
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
taxifolin inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of STAT1 protein] |
CTD |
PMID:12044887 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Colistin results in decreased expression of STAT3 protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of STAT3 protein]] |
CTD |
PMID:33882723 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]; taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TGFB1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]] |
CTD |
PMID:33840231 PMID:33882723 PMID:35465754 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
taxifolin inhibits the reaction [Rotenone results in decreased activity of TH protein] |
CTD |
PMID:35187747 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TLR4 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TLR4 protein]] |
CTD |
PMID:33840231 PMID:33882723 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
taxifolin inhibits the reaction [Chlorpyrifos results in increased secretion of TNF protein] taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TNF protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TNF protein]] |
CTD |
PMID:31152760 PMID:32828744 PMID:33882723 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
increases expression |
ISO |
taxifolin results in increased expression of TRAF3 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 6:136,025,097...136,128,363
Ensembl chr 6:130,206,484...130,305,481
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression decreases activity |
ISO EXP |
taxifolin results in increased expression of TXNRD1 mRNA taxifolin results in decreased activity of TXNRD1 protein modified form |
CTD |
PMID:16618767 PMID:17541156 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP |
taxifolin analog inhibits the reaction [Dietary Fats results in decreased expression of UCP1 mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
taxifolin results in increased expression of UGT1A1 mRNA AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:29584932 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO EXP |
taxifolin inhibits the reaction [XDH protein results in increased chemical synthesis of Superoxides] taxifolin inhibits the reaction [Rotenone results in increased activity of XDH protein] |
CTD |
PMID:19555678 PMID:35187747 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
increases expression |
ISO |
taxifolin results in increased expression of XPA mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 5:65,227,281...65,275,784
Ensembl chr 5:60,431,673...60,475,726
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
increases expression |
ISO |
taxifolin results in increased expression of XRCC4 mRNA |
CTD |
PMID:17541156 |
|
NCBI chr 2:22,686,506...22,932,929
Ensembl chr 2:20,951,200...21,197,808
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of ABCB1 mRNA naringenin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; naringenin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; naringenin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:19148864 PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions increases activity |
ISO |
[Glutathione co-treated with naringenin] inhibits the reaction [ABCC1 protein results in increased uptake of estradiol-17 beta-glucuronide]; Glutathione promotes the reaction [naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [naringenin results in increased activity of ABCC1 protein]; naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in increased export of S-(2,4-dinitrophenyl)glutathione]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased uptake of Glutathione] |
CTD |
PMID:11306701 PMID:12485947 PMID:16156793 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:16156793 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
naringenin inhibits the reaction [ABCC5 protein results in decreased susceptibility to Thioguanine]; naringenin inhibits the reaction [ABCC5 protein results in increased export of 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16156793 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein] |
CTD |
PMID:14709902 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ADGRB1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ADGRB1 mRNA naringenin metabolite results in increased expression of ADGRB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:108,293,681...108,365,892
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
naringenin binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity multiple interactions |
ISO |
naringenin results in increased activity of AHR protein naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]] |
CTD |
PMID:17869316 PMID:20450880 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
naringenin binds to and results in decreased activity of AKR1C1 protein |
CTD |
PMID:16962702 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
naringenin results in decreased activity of AKR1C3 protein |
CTD |
PMID:19007764 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO EXP |
naringenin inhibits the reaction [bisphenol A results in increased activity of AKT1 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of AKT1 protein] naringenin results in decreased expression of AKT1 mRNA naringenin inhibits the reaction [lead acetate results in decreased expression of AKT1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22692793 PMID:22709785 PMID:25866363 PMID:36807407 PMID:36819991 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in increased expression of ALB protein]; naringenin inhibits the reaction [tyloxapol results in decreased expression of ALB mRNA] |
CTD |
PMID:31063766 PMID:37076581 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein] |
CTD |
PMID:12650720 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of APAF1 mRNA; naringenin results in increased expression of APAF1 protein [naringenin co-treated with bisphenol A] results in increased expression of APAF1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of APAF1 mRNA |
CTD |
PMID:27838343 PMID:36235125 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
naringenin inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:15030205 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
naringenin results in increased expression of ARHGDIA mRNA; naringenin results in increased expression of ARHGDIA protein |
CTD |
PMID:27838343 |
|
NCBI chr10:106,352,858...106,356,347
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]] |
CTD |
PMID:20450880 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ATM mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ATM mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ATR mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ATR mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bace1 |
beta-secretase 1 |
decreases activity |
ISO |
naringenin results in decreased activity of BACE1 protein |
CTD |
PMID:31194956 |
|
NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
naringenin results in increased expression of BAK1 protein |
CTD |
PMID:27838343 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in increased expression of BAX mRNA]; naringenin inhibits the reaction [Glucose results in increased expression of BAX protein] [naringenin metabolite co-treated with bisphenol A] results in increased expression of BAX mRNA; naringenin inhibits the reaction [Pyruvaldehyde results in increased expression of BAX protein]; naringenin inhibits the reaction [Tamoxifen results in decreased expression of BAX mRNA]; Tamoxifen promotes the reaction [naringenin results in decreased expression of BAX mRNA] |
CTD |
PMID:23192364 PMID:30153467 PMID:31254498 PMID:36235125 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BBC3 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BBC3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] |
CTD |
PMID:23085349 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
[naringenin co-treated with bisphenol A] results in increased expression of BCL2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BCL2 mRNA; ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [BCL2 protein results in decreased susceptibility to naringenin]; naringenin inhibits the reaction [Pyruvaldehyde results in decreased expression of BCL2 protein]; naringenin promotes the reaction [Tamoxifen results in decreased expression of BCL2 mRNA] naringenin results in decreased expression of BCL2 mRNA naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:19124070 PMID:23192364 PMID:30153467 PMID:31254498 PMID:36235125 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of BCL2A1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BCL2A1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BCL2A1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
naringenin results in decreased expression of BCL2L1 protein |
CTD |
PMID:27838343 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in decreased expression of BDNF mRNA] naringenin results in increased expression of BDNF mRNA |
CTD |
PMID:34655599 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BIRC5 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BIRC5 mRNA naringenin metabolite results in increased expression of BIRC5 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BRCA1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BRCA1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of BRCA2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BRCA2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BRCA2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr12:4,895,092...4,939,340
Ensembl chr12:59,819...100,567
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression multiple interactions |
ISO |
naringenin metabolite results in decreased expression of BTG2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BTG2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BTG2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CASP2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CASP2 mRNA naringenin results in increased expression of CASP2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
ISO EXP |
naringenin results in increased activity of CASP3 protein naringenin results in increased expression of CASP3 mRNA naringenin inhibits the reaction [Pyruvaldehyde results in increased activity of CASP3 protein] naringenin results in increased expression of CASP3 protein modified form naringenin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; naringenin inhibits the reaction [methylmercuric chloride results in increased expression of CASP3 protein]; naringenin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] |
CTD |
PMID:19124070 PMID:22692793 PMID:23192364 PMID:27838343 PMID:31254498 PMID:34655599 PMID:38308452 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
naringenin results in increased expression of CASP7 protein modified form |
CTD |
PMID:27838343 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases expression |
ISO EXP |
naringenin results in increased activity of CASP9 protein [naringenin co-treated with bisphenol A] results in increased expression of CASP9 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CASP9 mRNA; naringenin inhibits the reaction [Pyruvaldehyde results in increased activity of CASP9 protein] naringenin metabolite results in increased expression of CASP9 mRNA; naringenin results in increased expression of CASP9 mRNA; naringenin results in increased expression of CASP9 protein modified form naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP9 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP9 mRNA] |
CTD |
PMID:19124070 PMID:23192364 PMID:27838343 PMID:31254498 PMID:36235125 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression increases activity |
EXP ISO |
naringenin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; naringenin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CAT protein]; naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of CAT protein]; naringenin inhibits the reaction [Cadmium results in decreased activity of CAT protein]; naringenin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; naringenin inhibits the reaction [Glucose results in decreased activity of CAT protein]; naringenin inhibits the reaction [lead acetate results in decreased activity of CAT protein]; naringenin inhibits the reaction [Paraquat results in increased activity of CAT protein]; naringenin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] naringenin inhibits the reaction [Trichloroethylene results in decreased activity of CAT protein] naringenin results in decreased expression of CAT protein naringenin analog results in increased activity of CAT protein; naringenin results in increased activity of CAT protein naringenin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:19063931 PMID:19409769 PMID:23192364 PMID:23283742 PMID:23845967 PMID:25855085 PMID:27206700 PMID:27417253 PMID:28395574 PMID:29223569 PMID:30372826 PMID:34655599 PMID:36807407 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in decreased expression of CCND1 mRNA naringenin results in decreased expression of CCND1 mRNA |
CTD |
PMID:30153467 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression multiple interactions |
ISO |
naringenin results in decreased expression of CCNE1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of CCNE1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNE1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in decreased expression of CCNG1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccnh |
cyclin H |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNH mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:17,570,449...17,591,078
Ensembl chr 2:15,834,833...15,855,819
|
|
G |
Cdc25a |
cell division cycle 25A |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDC25A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDC25A mRNA naringenin metabolite results in increased expression of CDC25A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDC25C mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDC25C mRNA |
CTD |
PMID:36235125 |
|
NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in decreased expression of CDK1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDK1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDK4 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDKN1A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDKN1A mRNA; [Tamoxifen co-treated with naringenin] results in increased expression of CDKN1A mRNA naringenin metabolite results in increased expression of CDKN1A mRNA; naringenin results in increased expression of CDKN1A mRNA |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDKN2A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CHEK1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CHEK1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CHEK2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CHEK2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CRADD mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CRADD mRNA naringenin results in increased expression of CRADD mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:29,798,586...29,952,907
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of CTNNB1 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of CTNNB1 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of CTSD mRNA |
CTD |
PMID:24586459 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose affects the localization of CYCS protein] naringenin results in increased expression of CYCS protein |
CTD |
PMID:23192364 PMID:27838343 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO EXP |
naringenin binds to and results in decreased activity of CYP19A1 protein naringenin results in decreased activity of CYP19A1 protein |
CTD |
PMID:9435150 PMID:15319488 PMID:17895526 PMID:38403145 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases expression |
ISO EXP |
naringenin binds to and results in decreased activity of CYP1A1 protein; naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] naringenin results in decreased activity of CYP1A1 protein naringenin results in increased expression of CYP1A1 mRNA naringenin promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:11454723 PMID:20930378 PMID:21053930 PMID:27444380 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
naringenin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 PMID:29753067 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
naringenin binds to and results in decreased activity of CYP1B1 protein naringenin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21053930 PMID:31621310 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
naringenin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO EXP |
naringenin results in decreased activity of CYP2E1 protein |
CTD |
PMID:33007396 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
naringenin results in decreased activity of CYP3A4 protein naringenin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:19148864 PMID:21053930 PMID:29753067 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of DNMT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of DNMT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of DRD2 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of DRD2 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of E2F1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of E2F1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of E2F3 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of E2F3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of EGFR mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of EGFR mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] |
CTD |
PMID:25866363 PMID:36235125 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of EGR1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of EGR1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Esr1 |
estrogen receptor 1 |
affects activity increases expression decreases expression affects binding increases activity multiple interactions |
ISO EXP |
naringenin affects the activity of ESR1 protein naringenin metabolite results in increased expression of ESR1 mRNA; naringenin results in increased expression of ESR1 mRNA naringenin results in decreased expression of ESR1 mRNA; naringenin results in decreased expression of ESR1 mRNA alternative form; naringenin results in decreased expression of ESR1 protein alternative form naringenin binds to ESR1 protein naringenin results in increased activity of ESR1 protein [naringenin binds to ESR1 protein] which results in increased activity of ALPL protein; [naringenin co-treated with bisphenol A] results in increased expression of ESR1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ESR1 mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of CTSD mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PGR mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PSEN2 mRNA; [SB 203580 co-treated with naringenin] results in increased degradation of ESR1 protein; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 mRNA alternative form; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 protein; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 protein alternative form; Fulvestrant inhibits the reaction [[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein]; naringenin binds to and results in increased activity of ESR1 protein; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; naringenin promotes the reaction [ESR1 protein binds to ESR1 protein]; naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein |
CTD |
PMID:9751507 PMID:10397250 PMID:10854714 PMID:12650720 PMID:15185748 PMID:15713566 PMID:16118406 PMID:19913605 PMID:22692793 PMID:24586459 PMID:30153467 PMID:36235125 More...
|
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression increases activity affects binding |
ISO EXP |
[Tamoxifen co-treated with naringenin] results in increased expression of ESR2 mRNA; [Tamoxifen co-treated with naringenin] results in increased expression of ESR2 protein; bisphenol A inhibits the reaction [naringenin metabolite results in increased expression of ESR2 mRNA]; bisphenol A inhibits the reaction [naringenin results in increased expression of ESR2 mRNA]; naringenin binds to and results in increased activity of ESR2 protein; naringenin inhibits the reaction [Estradiol binds to ESR2 protein] naringenin metabolite results in increased expression of ESR2 mRNA; naringenin results in increased expression of ESR2 mRNA; naringenin results in increased expression of ESR2 protein naringenin results in increased activity of ESR2 protein naringenin binds to ESR2 protein |
CTD |
PMID:9751507 PMID:12224631 PMID:16118406 PMID:16566672 PMID:17716812 PMID:19913605 PMID:30153467 PMID:36235125 More...
|
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of FADD mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of FAS mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of FAS mRNA naringenin metabolite results in increased expression of FAS mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of FASLG mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of FASLG mRNA naringenin metabolite results in increased expression of FASLG mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
naringenin results in increased expression of FOS mRNA |
CTD |
PMID:28395574 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of FOXO3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions decreases activity |
EXP ISO |
[naringenin co-treated with lead acetate] results in decreased activity of G6PD protein; naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of G6PD protein] naringenin results in decreased activity of G6PD protein |
CTD |
PMID:19063931 PMID:25130191 PMID:25228019 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of GADD45A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of GADD45A mRNA naringenin metabolite results in increased expression of GADD45A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLC protein] |
CTD |
PMID:31254498 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of GCLM protein NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLM protein] |
CTD |
PMID:31254498 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gml |
glycosylphosphatidylinositol anchored molecule like |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of GML mRNA [naringenin co-treated with bisphenol A] results in increased expression of GML mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of GML mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:106,683,749...106,712,802
Ensembl chr 7:106,689,410...106,712,724
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in decreased expression of GPER1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of GPER1 protein naringenin metabolite results in decreased expression of GPER1 mRNA; naringenin results in decreased expression of GPER1 mRNA; naringenin results in decreased expression of GPER1 protein |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr12:20,331,073...20,336,527
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
[naringenin co-treated with methylmercuric chloride] results in decreased activity of GPT protein; naringenin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein]; naringenin inhibits the reaction [Streptozocin results in increased activity of GPT protein] |
CTD |
PMID:23283742 PMID:29223569 PMID:38308452 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in decreased expression of GPX1 mRNA] naringenin results in decreased expression of GPX1 protein |
CTD |
PMID:23192364 PMID:28395574 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX2 mRNA naringenin results in increased expression of GPX2 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX3 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx5 |
glutathione peroxidase 5 |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of GPX5 mRNA [Paraquat co-treated with naringenin] results in increased expression of GPX5 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr17:48,131,853...48,138,801
Ensembl chr17:43,416,340...43,443,074
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX7 mRNA naringenin results in increased expression of GPX7 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 5:128,373,881...128,381,866
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
EXP ISO |
naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of GSR protein]; naringenin inhibits the reaction [Glucose results in decreased expression of GSR mRNA] Paraquat inhibits the reaction [naringenin results in increased expression of GSR mRNA] |
CTD |
PMID:19063931 PMID:23192364 PMID:24561720 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
multiple interactions increases expression |
ISO |
Paraquat inhibits the reaction [naringenin results in increased expression of GSTZ1 mRNA] |
CTD |
PMID:24561720 |
|
NCBI chr 6:112,525,576...112,536,228
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [Carbon Tetrachloride results in increased expression of HAVCR1 protein] |
CTD |
PMID:23845967 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hk2 |
hexokinase 2 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of HK2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of HK2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of HK2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringenin results in increased expression of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of and results in decreased activity of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of HMOX1 mRNA]; naringenin results in increased expression of and results in increased activity of HMOX1 protein; wortmannin inhibits the reaction [naringenin results in increased expression of HMOX1 protein] naringenin results in increased expression of HMOX1 mRNA; naringenin results in increased expression of HMOX1 protein [Paraquat co-treated with naringenin] results in increased expression of HMOX1 mRNA naringenin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein] |
CTD |
PMID:15316927 PMID:22709785 PMID:24561720 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of IGF1R mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of IGF1R mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
ISO |
naringenin results in increased expression of IKBKB mRNA |
CTD |
PMID:28395574 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
naringenin inhibits the reaction [lead acetate results in increased expression of IL1B protein] naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:36807407 PMID:37880698 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of IL6 mRNA naringenin inhibits the reaction [tyloxapol results in increased expression of IL6 mRNA] [naringenin co-treated with bisphenol A] results in increased expression of IL6 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of IL6 mRNA |
CTD |
PMID:36235125 PMID:37076581 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; naringenin inhibits the reaction [ITGA4 protein results in increased expression of TEK protein]; naringenin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO |
naringenin metabolite results in decreased expression of JUN mRNA; naringenin results in decreased expression of JUN mRNA naringenin results in increased expression of JUN mRNA |
CTD |
PMID:28395574 PMID:36235125 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of KAT2B mRNA [naringenin co-treated with bisphenol A] results in increased expression of KAT2B mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of KAT2B mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Amiodarone promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; azimilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; dofetilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Amiodarone results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [azimilide results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [dofetilide results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Quinidine results in decreased activity of KCNH2 protein]; Quinidine promotes the reaction [naringenin results in decreased activity of KCNH2 protein] |
CTD |
PMID:18057881 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein] |
CTD |
PMID:36731809 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of KRAS mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:179,916,255...179,949,613
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
naringenin inhibits the reaction [lead acetate results in decreased expression of LHB protein] |
CTD |
PMID:36807407 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpo |
lactoperoxidase |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of LPO mRNA Paraquat inhibits the reaction [naringenin results in increased expression of LPO mRNA] |
CTD |
PMID:24561720 |
|
NCBI chr10:73,104,170...73,124,683
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Lrrc27 |
leucine rich repeat containing 27 |
increases expression |
ISO |
naringenin results in increased expression of LRRC27 mRNA; naringenin results in increased expression of LRRC27 protein |
CTD |
PMID:27838343 |
|
NCBI chr 1:203,433,463...203,464,683
Ensembl chr 1:194,005,182...194,035,084
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of LRRK2 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of LRRK2 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases expression |
ISO |
naringenin results in increased expression of MAP3K5 protein |
CTD |
PMID:27838343 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression decreases activity decreases phosphorylation |
EXP ISO |
naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] naringenin results in decreased expression of MAPK1 mRNA naringenin results in decreased activity of MAPK1 protein naringenin results in decreased phosphorylation of MAPK1 protein naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20450880 PMID:22709785 PMID:25866363 PMID:27468969 PMID:30431227 PMID:36819991 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases activity decreases phosphorylation |
EXP ISO |
naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] naringenin results in decreased activity of MAPK3 protein naringenin results in decreased phosphorylation of MAPK3 protein naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20450880 PMID:22709785 PMID:25866363 PMID:27468969 PMID:30431227 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
naringenin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:27838343 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
naringenin results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:27838343 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MCL1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MCL1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdk |
midkine |
multiple interactions |
EXP |
naringenin inhibits the reaction [MDK protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MDM2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MDM2 mRNA naringenin metabolite results in increased expression of MDM2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MDM4 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MDM4 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:46,922,236...47,068,241
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mir141 |
microRNA 141 |
decreases expression |
ISO |
naringenin metabolite results in decreased expression of MIR141 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:159,209,525...159,209,618
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir200c |
microRNA 200c |
multiple interactions |
ISO |
naringenin inhibits the reaction [bisphenol A results in increased expression of MIR200C mRNA]; naringenin metabolite inhibits the reaction [bisphenol A results in increased expression of MIR200C mRNA] |
CTD |
PMID:36235125 |
|
NCBI chr 4:159,209,965...159,210,033
|
|
G |
Mlh1 |
mutL homolog 1 |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of MLH1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of MLH1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MLH1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
ISO |
naringenin results in decreased expression of MMP2 mRNA naringenin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:30153467 PMID:30431227 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased secretion of MMP9 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; naringenin results in decreased expression of and results in decreased activity of MMP9 protein naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein] naringenin results in decreased expression of MMP9 mRNA |
CTD |
PMID:25866363 PMID:30153467 PMID:30431227 PMID:37880698 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of MSH2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
naringenin inhibits the reaction [lead acetate results in decreased expression of MTOR protein] |
CTD |
PMID:36807407 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myod1 |
myogenic differentiation 1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of MYOD1 mRNA; naringenin results in increased expression of MYOD1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of MYOD1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MYOD1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
naringenin results in decreased expression of NANOG protein |
CTD |
PMID:27468969 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of NF1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of NF1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity increases expression |
ISO |
[naringenin co-treated with Paraquat] results in increased expression of NFE2L2 protein; naringenin results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLM protein] naringenin results in increased activity of NFE2L2 protein naringenin results in increased expression of NFE2L2 mRNA |
CTD |
PMID:24561720 PMID:31254498 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of NFKB1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of NFKB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
naringenin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:10188978 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbil1 |
NFKB inhibitor like 1 |
increases expression |
ISO |
naringenin results in increased expression of NFKBIL1 mRNA; naringenin results in increased expression of NFKBIL1 protein |
CTD |
PMID:27838343 |
|
NCBI chr20:3,595,319...3,610,295
Ensembl chr20:3,590,642...3,605,616
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
ISO |
naringenin results in increased expression of NME1 mRNA; naringenin results in increased expression of NME1 protein |
CTD |
PMID:27838343 |
|
NCBI chr10:79,403,939...79,426,620
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; naringenin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:10188978 PMID:12512693 PMID:15316927 PMID:18274639 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of NQO1 mRNA naringenin results in increased expression of NQO1 mRNA; naringenin results in increased expression of NQO1 protein |
CTD |
PMID:24561720 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
naringenin results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
naringenin results in increased cleavage of PARP1 protein naringenin inhibits the reaction [Pyruvaldehyde results in increased cleavage of PARP1 protein] |
CTD |
PMID:27838343 PMID:31254498 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PCNA mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PCNA mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
naringenin results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
EXP ISO |
naringenin results in increased expression of PGR mRNA [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PGR mRNA |
CTD |
PMID:10397250 PMID:24586459 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PIDD1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PIDD1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:205,966,392...205,972,359
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
naringenin results in increased expression of PON1 mRNA |
CTD |
PMID:15169886 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein] naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARA protein] |
CTD |
PMID:31063766 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARB protein] HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein] |
CTD |
PMID:31063766 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]; naringenin inhibits the reaction [Streptozocin results in decreased expression of PPARG mRNA]; naringenin inhibits the reaction [Streptozocin results in decreased expression of PPARG protein] naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARG protein] |
CTD |
PMID:29223569 PMID:31063766 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PPM1D mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PPM1D mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:70,670,026...70,706,030
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
ISO |
naringenin results in decreased expression of PRDX1 mRNA; naringenin results in decreased expression of PRDX1 protein |
CTD |
PMID:27838343 |
|
NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PRKCA mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PRKCA mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] |
CTD |
PMID:25866363 PMID:36235125 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCB protein] |
CTD |
PMID:25866363 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCG protein] |
CTD |
PMID:25866363 |
|
NCBI chr 1:74,748,272...74,777,611
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
ISO |
naringenin results in decreased expression of PROM1 protein |
CTD |
PMID:27468969 |
|
NCBI chr14:71,202,303...71,307,008
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
[naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PSEN2 mRNA |
CTD |
PMID:24586459 |
|
NCBI chr13:94,499,451...94,528,419
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of PTEN mRNA naringenin results in increased expression of PTEN mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
naringenin results in increased expression of PTGS1 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] naringenin inhibits the reaction [Trichloroethylene results in increased expression of PTGS2 protein] naringenin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:21341175 PMID:25855085 PMID:27206700 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of PTTG1 mRNA [naringenin metabolite co-treated with bisphenol A] results in increased expression of PTTG1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of RB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein] naringenin inhibits the reaction [Trichloroethylene results in increased expression of RELA protein] naringenin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein]; naringenin inhibits the reaction [MDK protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:18274639 PMID:25855085 PMID:27206700 PMID:36731809 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of RPRM mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of RPRM mRNA naringenin metabolite results in increased expression of RPRM mRNA; naringenin results in increased expression of RPRM mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:58,948,618...58,950,035
Ensembl chr 3:38,539,581...38,540,998
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases expression |
ISO |
naringenin results in increased expression of RPTOR mRNA; naringenin results in increased expression of RPTOR protein |
CTD |
PMID:27838343 |
|
NCBI chr10:105,376,943...105,675,416
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:22709785 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of SESN2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of SESN2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
naringenin binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Si |
sucrase-isomaltase |
decreases activity multiple interactions |
EXP ISO |
naringenin results in decreased activity of SI protein naringenin binds to and results in decreased activity of SI protein |
CTD |
PMID:24412302 |
|
NCBI chr 2:159,804,568...159,884,902
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Siah1 |
siah E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of SIAH1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr19:36,552,165...36,575,773
Ensembl chr19:20,378,439...20,403,808
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of SIRT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of SIRT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] [naringenin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 PMID:17976262 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions decreases activity |
ISO |
naringenin inhibits the reaction [SLC2A1 protein affects the transport of Glucose] naringenin results in decreased activity of SLC2A1 protein |
CTD |
PMID:14642735 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 mRNA]; naringenin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:29223569 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:81,778,495...81,843,084
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of SLC6A3 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of SLC6A3 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
naringenin inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein] |
CTD |
PMID:22394605 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
naringenin results in decreased expression of SNAI1 protein |
CTD |
PMID:30431227 |
|
NCBI chr 3:176,667,476...176,671,965
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
naringenin results in decreased expression of SNAI2 protein |
CTD |
PMID:30431227 |
|
NCBI chr11:99,686,934...99,690,349
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in increased expression of SNCA mRNA] naringenin results in increased expression of SNCA mRNA |
CTD |
PMID:34655599 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
naringenin results in increased expression of SOCS3 mRNA |
CTD |
PMID:23782265 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in increased expression of SOD1 mRNA] naringenin results in decreased expression of SOD1 protein |
CTD |
PMID:23192364 PMID:28395574 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA] |
CTD |
PMID:23192364 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
naringenin results in decreased expression of SOX2 protein |
CTD |
PMID:27468969 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [TNF protein results in increased expression of SPP1 mRNA] |
CTD |
PMID:22709785 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of STAT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
naringenin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:27468969 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO EXP |
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of naringenin] |
CTD |
PMID:11181495 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tada3 |
transcriptional adaptor 3 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of TADA3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:148,065,859...148,077,347
Ensembl chr 4:146,510,246...146,521,590
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of TEK protein] |
CTD |
PMID:36731809 |
|
NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] naringenin inhibits the reaction [lead acetate results in increased expression of TGFB1 protein] |
CTD |
PMID:23845967 PMID:36807407 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in decreased expression of TH protein] naringenin results in decreased expression of TH protein |
CTD |
PMID:34655599 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression decreases activity |
ISO EXP |
[naringenin co-treated with bisphenol A] results in increased expression of TNF mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TNF mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] naringenin metabolite results in increased expression of TNF mRNA naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; naringenin inhibits the reaction [tyloxapol results in increased expression of TNF mRNA] naringenin results in decreased activity of TNF protein naringenin inhibits the reaction [lead acetate results in increased expression of TNF protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of and results in decreased activity of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of HMOX1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased expression of SPP1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin inhibits the reaction [naringenin results in decreased activity of TNF protein] |
CTD |
PMID:18720166 PMID:19135038 PMID:22709785 PMID:36235125 PMID:36807407 PMID:37076581 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in increased expression of TP53 mRNA; naringenin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein]; naringenin results in increased expression of and results in increased phosphorylation of TP53 protein naringenin results in increased expression of TP53 mRNA |
CTD |
PMID:15795422 PMID:27838343 PMID:30153467 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp2 |
tumor protein p53 binding protein, 2 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of TP53BP2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:96,620,429...96,677,090
Ensembl chr13:94,088,709...94,145,432
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TP63 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TP63 mRNA naringenin metabolite results in increased expression of TP63 mRNA; naringenin results in increased expression of TP63 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tp73 |
tumor protein p73 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of TP73 mRNA; naringenin results in increased expression of TP73 mRNA [naringenin co-treated with bisphenol A] results in increased expression of TP73 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TP73 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tpo |
thyroid peroxidase |
decreases activity |
EXP |
naringenin results in decreased activity of TPO protein |
CTD |
PMID:26884060 |
|
NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TRAF2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TRAF2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:28,740,098...28,764,752
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TSC1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:32,367,434...32,416,565
Ensembl chr 3:11,979,729...12,015,674
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dietary Fats results in decreased expression of UCP1 mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation increases expression |
ISO |
UGT1A1 protein results in increased glucuronidation of naringenin naringenin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:14557274 PMID:31621310 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of naringenin |
CTD |
PMID:14557274 PMID:18816295 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of naringenin |
CTD |
PMID:7574722 |
|
NCBI chr14:21,122,866...21,138,450
Ensembl chr14:20,768,015...20,783,589
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [tyloxapol results in increased expression of VEGFA mRNA] naringenin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 PMID:37076581 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of WT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of WT1 mRNA naringenin metabolite results in increased expression of WT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:112,019,721...112,068,454
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
naringenin inhibits the reaction [Benzo(a)pyrene results in increased activity of XDH protein] |
CTD |
PMID:27206700 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of XRCC5 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:81,404,507...81,493,293
Ensembl chr 9:73,955,216...74,044,018
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
3-hydroxyflavanone binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
3-hydroxyflavanone binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
4'-hydroxyflavanone binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
4'-hydroxyflavanone binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
6-prenylnaringenin results in increased expression of CYP1A1 mRNA; 6-prenylnaringenin results in increased expression of CYP1A1 protein 6-prenylnaringenin inhibits the reaction [DNMT1 protein binds to CYP1A1 promoter]; 6-prenylnaringenin inhibits the reaction [Estradiol promotes the reaction [DNMT1 protein binds to CYP1A1 promoter]]; 6-prenylnaringenin inhibits the reaction [Estradiol results in decreased expression of CYP1A1 mRNA] |
CTD |
PMID:27269377 PMID:32986415 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
6-prenylnaringenin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27269377 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
6-prenylnaringenin inhibits the reaction [DNMT1 protein binds to CYP1A1 promoter]; 6-prenylnaringenin inhibits the reaction [Estradiol promotes the reaction [DNMT1 protein binds to CYP1A1 promoter]] |
CTD |
PMID:32986415 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein]; 6-prenylnaringenin promotes the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein] |
CTD |
PMID:32986415 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
7-hydroxyflavanone binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
7-hydroxyflavanone results in decreased activity of CYP19A1 protein |
CTD |
PMID:15319488 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
7-hydroxyflavanone binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[astilbin co-treated with Cisplatin] results in increased expression of AKR1C1 mRNA |
CTD |
PMID:29471006 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:29471006 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:29471006 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased expression of GCLC mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin results in increased expression of GCLM mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of IL6 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin affects the localization of NFE2L2 protein] astilbin promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29471006 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin results in increased expression of TNF mRNA] astilbin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:29471006 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] |
CTD |
PMID:29471006 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased expression of ADGRE1 protein; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with bavachinin] results in increased expression of ADGRE1 protein] |
CTD |
PMID:38969277 |
|
NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Aim2 |
absent in melanoma 2 |
multiple interactions |
ISO |
AIM2 protein affects the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein]; AIM2 protein affects the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein] |
CTD |
PMID:38969277 |
|
NCBI chr13:88,397,516...88,439,325
Ensembl chr13:85,866,284...85,906,975
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
bavachinin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:37358659 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
bavachinin results in decreased expression of BCL2 protein |
CTD |
PMID:37358659 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases cleavage |
ISO |
[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein; [ODN A151 co-treated with carnosol] inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein]; AIM2 protein affects the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein]; bavachinin promotes the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; carnosol inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein]; Lipopolysaccharides promotes the reaction [bavachinin results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein]; ODN A151 inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased activity of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:38969277 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
bavachinin results in decreased expression of CASP9 protein |
CTD |
PMID:37358659 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
ISO |
bavachinin results in decreased activity of CES1 protein |
CTD |
PMID:26560012 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
bavachinin inhibits the reaction [COL2A1 protein results in decreased expression of IL10 protein]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL1B mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL6 mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of TNF mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of TNF protein] |
CTD |
PMID:37358659 |
|
NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
bavachinin results in increased expression of CYCS protein |
CTD |
PMID:37358659 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased expression of GPT protein; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with bavachinin] results in increased expression of GPT protein] |
CTD |
PMID:38969277 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions increases cleavage |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased cleavage of GSDMD protein; [Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased cleavage of GSDMD protein; bavachinin promotes the reaction [Lipopolysaccharides results in increased expression of GSDMD mRNA] bavachinin results in increased cleavage of GSDMD protein |
CTD |
PMID:38969277 |
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO |
bavachinin results in increased expression of IL10 mRNA; bavachinin results in increased expression of IL10 protein bavachinin inhibits the reaction [COL2A1 protein results in decreased expression of IL10 protein] |
CTD |
PMID:37358659 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
bavachinin results in decreased expression of IL1B mRNA; bavachinin results in decreased expression of IL1B protein [Lipopolysaccharides co-treated with bavachinin] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with bavachinin] results in increased expression of IL1B protein; [Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein; [ODN A151 co-treated with carnosol] inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein]; AIM2 protein affects the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL1B mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; carnosol inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with bavachinin] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein]; ODN A151 inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to bavachinin] which results in increased expression of IL1B protein] |
CTD |
PMID:37358659 PMID:38969277 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
bavachinin results in decreased expression of IL6 mRNA; bavachinin results in decreased expression of IL6 protein bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL6 mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; bavachinin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:37358659 PMID:38969277 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irgm |
immunity-related GTPase M |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased expression of IRGM1 mRNA |
CTD |
PMID:38969277 |
|
NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Nek7 |
NIMA-related kinase 7 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased expression of NEK7 mRNA |
CTD |
PMID:38969277 |
|
NCBI chr13:52,573,730...52,700,869
Ensembl chr13:50,022,218...50,149,296
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with bavachinin] results in increased expression of NLRP3 mRNA |
CTD |
PMID:38969277 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
bavachinin results in increased expression of PPARG mRNA; bavachinin results in increased expression of PPARG protein |
CTD |
PMID:37358659 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased susceptibility to bavachinin] promotes the reaction [PYCARD protein binds to PYCARD protein] |
CTD |
PMID:38969277 |
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
bavachinin results in decreased expression of TNF mRNA; bavachinin results in decreased expression of TNF protein [Lipopolysaccharides co-treated with bavachinin] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with bavachinin] results in increased expression of TNF protein; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of TNF mRNA]; bavachinin inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with bavachinin] results in increased expression of TNF protein] |
CTD |
PMID:37358659 PMID:38969277 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of AR protein] |
CTD |
PMID:31797688 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 PMID:31797688 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of ENO2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of and results in decreased activity of GPX1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of IL6 protein] |
CTD |
PMID:31797688 PMID:32061149 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of KLK3 protein] |
CTD |
PMID:31797688 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:29187079 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGER2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:29187079 PMID:31797688 PMID:32061149 PMID:35920545 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
eriocitrin results in increased expression of BAX protein |
CTD |
PMID:34724282 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
eriocitrin results in decreased expression of BCL2 protein |
CTD |
PMID:34724282 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
eriocitrin results in increased expression of CASP7 protein |
CTD |
PMID:34724282 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
eriocitrin results in increased expression of CASP9 protein |
CTD |
PMID:34724282 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
eriocitrin results in decreased expression of CCND1 protein |
CTD |
PMID:34724282 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
eriocitrin results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:34724282 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [eriocitrin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34724282 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
eriocitrin results in decreased expression of PCNA protein |
CTD |
PMID:34724282 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases phosphorylation |
ISO |
eriocitrin results in decreased phosphorylation of SRC protein |
CTD |
PMID:34724282 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
eriocitrin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:34724282 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[ABCB1 protein results in decreased susceptibility to Doxorubicin] affects the reaction [eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA]]; eriodictyol inhibits the reaction [[ABCB1 protein results in decreased susceptibility to Doxorubicin] promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ABCB1 mRNA]] |
CTD |
PMID:20438634 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
eriodictyol results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2A1 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
eriodictyol inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:28978146 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCL2 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCND1 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
eriodictyol results in increased expression of CYCS protein |
CTD |
PMID:37020356 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
eriodictyol results in decreased activity of CYP19A1 protein |
CTD |
PMID:38403145 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
eriodictyol inhibits the reaction [Arsenic Trioxide results in increased expression of GPT protein] |
CTD |
PMID:28978146 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases expression |
ISO |
eriodictyol results in decreased expression of GPX4 protein |
CTD |
PMID:37020356 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
ISO |
eriodictyol results in decreased activity of GSTP1 protein |
CTD |
PMID:15041478 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
eriodictyol results in increased expression of HMOX1 protein eriodictyol results in decreased expression of HMOX1 protein bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of HMOX1 protein] eriodictyol results in increased expression of HMOX1 mRNA; eriodictyol results in increased expression of HMOX1 protein eriodictyol promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 mRNA]; eriodictyol promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:28978146 PMID:37020356 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [IFNG protein results in increased abundance of Nitrites] |
CTD |
PMID:23942037 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:21544733 PMID:31860763 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA] |
CTD |
PMID:20438634 PMID:21544733 PMID:31860763 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:21544733 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:31860763 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression decreases expression decreases phosphorylation multiple interactions |
ISO EXP |
eriodictyol results in increased expression of NFE2L2 protein eriodictyol results in decreased expression of NFE2L2 protein eriodictyol results in decreased phosphorylation of NFE2L2 protein bardoxolone methyl inhibits the reaction [eriodictyol results in decreased phosphorylation of NFE2L2 protein] eriodictyol promotes the reaction [Arsenic Trioxide results in increased expression of NFE2L2 mRNA]; eriodictyol promotes the reaction [Arsenic Trioxide results in increased expression of NFE2L2 protein] eriodictyol results in increased expression of NFE2L2 mRNA; eriodictyol results in increased expression of NFE2L2 protein |
CTD |
PMID:16799064 PMID:28978146 PMID:37020356 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] |
CTD |
PMID:20438634 PMID:21544733 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein] |
CTD |
PMID:31860763 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
ISO |
eriodictyol results in decreased expression of NQO1 protein bardoxolone methyl inhibits the reaction [eriodictyol results in decreased expression of NQO1 protein] |
CTD |
PMID:37020356 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:31860763 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein] |
CTD |
PMID:20438634 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
eriodictyol results in decreased expression of SLC7A11 protein |
CTD |
PMID:37020356 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
decreases activity |
ISO |
eriodictyol results in decreased activity of TBK1 protein |
CTD |
PMID:19426678 |
|
NCBI chr 7:58,963,319...58,996,357
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases activity |
ISO |
eriodictyol inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] eriodictyol results in decreased activity of TNF protein |
CTD |
PMID:11123379 PMID:20438634 PMID:21544733 PMID:31860763 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[ABCB1 protein results in decreased susceptibility to Doxorubicin] affects the reaction [eriodictyol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA]]; eriodictyol affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA] |
CTD |
PMID:20438634 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
flavanone binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ar |
androgen receptor |
affects binding |
EXP |
flavanone binds to AR protein |
CTD |
PMID:14565775 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
flavanone results in increased expression of BAX protein |
CTD |
PMID:22056764 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone results in decreased activity of CASP3 protein] which results in decreased susceptibility to flavanone; flavanone results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:22056764 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] which results in decreased susceptibility to flavanone; flavanone results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:22056764 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
flavanone results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:22056764 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
flavanone results in increased expression of CDKN1A protein |
CTD |
PMID:22056764 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
flavanone results in increased expression of CDKN1B protein |
CTD |
PMID:22056764 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
flavanone affects the localization of CYCS protein |
CTD |
PMID:22056764 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression decreases activity |
ISO |
flavanone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] flavanone results in increased expression of CYP1A1 mRNA flavanone promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] flavanone results in decreased activity of CYP1A1 protein |
CTD |
PMID:17090139 PMID:20930378 PMID:21053930 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
flavanone results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
flavanone binds to and results in decreased activity of CYP1B1 protein flavanone analog results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21053930 PMID:31621310 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
flavanone inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; flavanone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] flavanone results in decreased activity of CYP3A4 protein |
CTD |
PMID:21053930 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
flavanone results in increased expression of FAS mRNA |
CTD |
PMID:22056764 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
flavanone results in increased expression of FASLG mRNA |
CTD |
PMID:22056764 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
flavanone results in decreased activity of MAOA protein |
CTD |
PMID:23009399 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
flavanone results in increased activity of NR1I3 protein |
CTD |
PMID:28927721 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
flavanone results in increased cleavage of PARP1 protein |
CTD |
PMID:22056764 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
flavanone results in increased expression of PPARG protein |
CTD |
PMID:22056764 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
flavanone results in increased expression of PTEN protein |
CTD |
PMID:22056764 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
flavanone results in decreased phosphorylation of RB1 protein |
CTD |
PMID:22056764 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
flavanone binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
flavanone results in increased expression of and results in increased phosphorylation of TP53 protein |
CTD |
PMID:22056764 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
flavanone analog results in increased expression of UGT1A1 mRNA |
CTD |
PMID:31621310 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in increased export of S-(2,4-dinitrophenyl)glutathione]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:16156793 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [ABCC4 protein results in decreased susceptibility to Thioguanine]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:16156793 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [ABCC5 protein results in decreased susceptibility to Thioguanine]; hesperetin inhibits the reaction [ABCC5 protein results in increased export of 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16156793 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[hesperetin analog co-treated with bisperoxovanadium analog] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; PTEN protein promotes the reaction [hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]] |
CTD |
PMID:27818223 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
hesperetin results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:25345581 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of AGER protein] |
CTD |
PMID:33522063 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity multiple interactions |
ISO |
hesperetin results in increased activity of AHR protein [2-hydroxypropyl-beta-cyclodextrin co-treated with hesperetin] inhibits the reaction [Benzo(a)pyrene results in increased expression of AHR protein] |
CTD |
PMID:17869316 PMID:21720915 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
hesperetin affects the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19222219 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of ALB protein] |
CTD |
PMID:34922902 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
affects binding |
ISO |
hesperetin binds to ALDH4A1 protein |
CTD |
PMID:37487865 |
|
NCBI chr 5:157,163,189...157,188,673
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
affects binding |
ISO |
hesperetin binds to APEX1 protein |
CTD |
PMID:37487865 |
|
NCBI chr15:26,618,146...26,620,330
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in decreased expression of ATG5 mRNA] |
CTD |
PMID:34933056 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression multiple interactions increases expression |
ISO EXP |
hesperetin affects the expression of BAX protein [Cisplatin co-treated with hesperetin] results in decreased expression of BAX protein hesperetin promotes the reaction [Cisplatin results in increased expression of BAX protein] hesperetin analog results in increased expression of BAX protein; hesperetin results in increased expression of BAX mRNA; hesperetin results in increased expression of BAX protein hesperetin analog results in increased expression of BAX mRNA |
CTD |
PMID:15975156 PMID:20564462 PMID:22142698 PMID:25345581 PMID:31153982 PMID:37487865 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO EXP |
hesperetin affects the expression of BCL2 protein hesperetin promotes the reaction [Cisplatin results in increased expression of BCL2 protein] hesperetin analog results in decreased expression of BCL2 protein; hesperetin results in decreased expression of BCL2 protein hesperetin analog results in decreased expression of BCL2 mRNA |
CTD |
PMID:15975156 PMID:20564462 PMID:22142698 PMID:31153982 PMID:37487865 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in decreased expression of BECN1 mRNA] |
CTD |
PMID:34933056 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
affects cleavage increases cleavage multiple interactions increases expression increases activity |
ISO EXP |
hesperetin affects the cleavage of CASP3 protein hesperetin results in increased cleavage of CASP3 protein Acetylcysteine inhibits the reaction [hesperetin results in increased cleavage of CASP3 protein]; hesperetin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] hesperetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein] hesperetin metabolite results in increased expression of CASP3 protein modified form; hesperetin results in increased expression of CASP3 protein modified form hesperetin analog results in increased activity of CASP3 protein hesperetin analog results in increased expression of CASP3 mRNA |
CTD |
PMID:15975156 PMID:19222219 PMID:20564462 PMID:22142698 PMID:31153982 PMID:37487865 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity multiple interactions decreases activity |
ISO EXP |
hesperetin results in increased activity of CAT protein hesperetin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CAT protein] hesperetin analog results in decreased activity of CAT protein; hesperetin results in decreased activity of CAT protein hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of CAT protein]; hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CAT protein]; hesperetin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; hesperetin inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:19023542 PMID:19222219 PMID:19497424 PMID:21134734 PMID:22142698 PMID:26546711 PMID:34922902 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:24707119 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein] |
CTD |
PMID:24707119 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO EXP |
hesperetin results in decreased expression of CCND1 hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of CCND1 protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein] |
CTD |
PMID:17927510 PMID:27818223 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
affects binding |
ISO |
hesperetin binds to CCS protein |
CTD |
PMID:37487865 |
|
NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
hesperetin results in decreased expression of CDK2 |
CTD |
PMID:17927510 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions decreases expression |
ISO |
hesperetin promotes the reaction [CDK4 protein binds to CDKN1A protein] hesperetin results in decreased expression of CDK4 |
CTD |
PMID:17927510 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
hesperetin promotes the reaction [CDK4 protein binds to CDKN1A protein] hesperetin results in increased expression of CDKN1A; hesperetin results in increased expression of CDKN1A mRNA |
CTD |
PMID:17927510 PMID:25345581 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
hesperetin results in increased expression of CDKN1B |
CTD |
PMID:17927510 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
hesperetin results in decreased expression of CEBPA protein |
CTD |
PMID:25345581 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
[hesperetin analog co-treated with bisperoxovanadium analog] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:27818223 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein] |
CTD |
PMID:24707119 |
|
NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
EXP |
hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYB5A protein] |
CTD |
PMID:19497424 |
|
NCBI chr18:80,487,923...80,520,544
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
hesperetin analog results in increased expression of CYCS protein; hesperetin results in increased expression of CYCS protein |
CTD |
PMID:22142698 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
hesperetin results in decreased activity of CYP19A1 protein |
CTD |
PMID:10403137 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
[2-hydroxypropyl-beta-cyclodextrin co-treated with hesperetin] inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] hesperetin results in decreased activity of CYP1A1 protein hesperetin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] |
CTD |
PMID:10781868 PMID:21720915 PMID:26546711 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
hesperetin results in decreased activity of CYP1A2 protein |
CTD |
PMID:29753067 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
hesperetin results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
hesperetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYP2E1 protein] |
CTD |
PMID:19497424 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dazl |
deleted in azoospermia-like |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in decreased expression of DAZL mRNA] |
CTD |
PMID:34933056 |
|
NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:10,695,592...10,712,323
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
hesperetin results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [hesperetin results in increased expression of DDIT3 protein] |
CTD |
PMID:37487865 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in increased expression of DNM1L mRNA]; hesperetin inhibits the reaction [Doxorubicin results in increased expression of DNM1L protein] |
CTD |
PMID:34933056 |
|
NCBI chr11:98,084,049...98,135,663
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
hesperetin results in decreased expression of FABP4 mRNA |
CTD |
PMID:25345581 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Cadmium Chloride results in decreased activity of G6PD protein] |
CTD |
PMID:21134734 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
affects binding |
ISO |
hesperetin binds to GPX4 protein |
CTD |
PMID:37487865 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of GSK3B protein] |
CTD |
PMID:34922902 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of GSR protein]; hesperetin inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein] hesperetin inhibits the reaction [Benzo(a)pyrene results in decreased activity of GSR protein] |
CTD |
PMID:21134734 PMID:26546711 PMID:35567572 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
hesperetin results in increased expression of HMOX1 protein [Cisplatin co-treated with hesperetin] results in increased expression of HMOX1 protein hesperetin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; hesperetin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein] |
CTD |
PMID:15316927 PMID:31153982 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
hesperetin results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [hesperetin results in increased expression of HSPA5 protein] |
CTD |
PMID:37487865 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ICAM1 protein] |
CTD |
PMID:33522063 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:24707119 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] |
CTD |
PMID:24707119 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions affects expression |
ISO EXP |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]] hesperetin affects the expression of IL1B protein |
CTD |
PMID:24707119 PMID:24871567 PMID:28428136 PMID:32762101 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects expression |
ISO EXP |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of IL6 protein]; hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein]] hesperetin affects the expression of IL6 protein |
CTD |
PMID:24707119 PMID:24871567 PMID:28428136 PMID:32762101 PMID:33522063 PMID:34922902 PMID:35567572 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
ISO |
hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of JAK1 protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of JAK1 protein] |
CTD |
PMID:28428136 |
|
NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:33522063 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
affects binding |
ISO |
hesperetin binds to KEAP1 protein |
CTD |
PMID:37487865 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
hesperetin results in decreased expression of LPL mRNA |
CTD |
PMID:25345581 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:31153982 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:31153982 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP ISO |
hesperetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein] [Cisplatin co-treated with hesperetin] results in decreased phosphorylation of MAPK8 protein hesperetin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19222219 PMID:31153982 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mir150 |
microRNA 150 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in decreased expression of MIR150 mRNA] |
CTD |
PMID:34933056 |
|
NCBI chr 1:104,741,487...104,741,571
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir181b2 |
microRNA 181b-2 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in decreased expression of MIR181B2 mRNA] |
CTD |
PMID:34933056 |
|
NCBI chr 3:43,026,666...43,026,753
Ensembl chr 3:22,616,948...22,617,035
|
|
G |
Mir410 |
microRNA 410 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MIR410 mRNA]; MIR410 mRNA affects the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SOX18 protein]]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein]]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]] |
CTD |
PMID:32762101 |
|
NCBI chr 6:134,579,763...134,579,838
Ensembl chr 6:128,758,354...128,758,434
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO EXP |
hesperetin inhibits the reaction [Cisplatin results in increased expression of MPO protein] hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:31153982 PMID:33522063 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Doxorubicin results in increased expression of MTOR mRNA]; hesperetin inhibits the reaction [Doxorubicin results in increased expression of MTOR protein] |
CTD |
PMID:34933056 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of MYC protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of MYC protein] |
CTD |
PMID:27818223 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO |
hesperetin inhibits the reaction [Benzo(a)pyrene results in decreased expression of NFE2L2 protein]; hesperetin promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein] [Cisplatin co-treated with hesperetin] results in increased expression of NFE2L2 protein hesperetin results in increased expression of NFE2L2 protein |
CTD |
PMID:26546711 PMID:31153982 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of NOS2 protein] |
CTD |
PMID:12512693 PMID:15316927 PMID:35567572 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
decreases expression multiple interactions |
ISO |
hesperetin results in decreased expression of NOX4 protein hesperetin inhibits the reaction [Cisplatin results in increased expression of NOX4 protein] |
CTD |
PMID:31153982 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP ISO |
hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of NQO1 protein] hesperetin inhibits the reaction [Cisplatin results in decreased expression of NQO1 protein] [Cisplatin co-treated with hesperetin] results in increased expression of NQO1 protein hesperetin results in increased expression of NQO1 protein |
CTD |
PMID:19497424 PMID:31153982 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
affects binding |
ISO |
hesperetin binds to NQO2 protein |
CTD |
PMID:37487865 |
|
NCBI chr17:31,114,825...31,144,062
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
hesperetin results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO EXP |
hesperetin inhibits the reaction [Benzo(a)pyrene results in increased expression of PCNA protein] hesperetin inhibits the reaction [Doxorubicin results in decreased expression of PCNA mRNA] |
CTD |
PMID:26546711 PMID:34933056 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
decreases expression multiple interactions |
ISO |
hesperetin results in decreased expression of PDCD6IP protein Acetylcysteine inhibits the reaction [hesperetin results in decreased expression of PDCD6IP protein] |
CTD |
PMID:37487865 |
|
NCBI chr 8:122,469,223...122,524,993
Ensembl chr 8:113,590,998...113,646,773
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of POR protein] |
CTD |
PMID:19497424 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
ISO |
hesperetin results in decreased expression of PPARG mRNA; hesperetin results in decreased expression of PPARG protein [hesperetin analog co-treated with PPARG protein] affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]; hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of JAK1 protein]]; hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in decreased expression of PPARG mRNA]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in decreased expression of PPARG protein]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG protein] |
CTD |
PMID:25345581 PMID:28428136 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
hesperetin analog inhibits the reaction [bisperoxovanadium analog promotes the reaction [TGFB1 protein results in decreased expression of PTEN protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in decreased expression of PTEN mRNA]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in decreased expression of PTEN protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; PTEN protein promotes the reaction [hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]] |
CTD |
PMID:27818223 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions affects activity |
ISO EXP |
hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PTGS2 protein] hesperetin affects the activity of PTGS2 protein |
CTD |
PMID:15240993 PMID:16101151 PMID:35567572 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
hesperetin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of RELA protein] |
CTD |
PMID:26546711 PMID:35567572 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
hesperetin results in decreased expression of RETN mRNA |
CTD |
PMID:25345581 |
|
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
hesperetin binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Sirt3 |
sirtuin 3 |
affects binding |
ISO |
hesperetin binds to SIRT3 protein |
CTD |
PMID:37487865 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sirt6 |
sirtuin 6 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with hesperetin] results in increased expression of SIRT6 protein hesperetin results in increased expression of SIRT6 protein |
CTD |
PMID:31153982 |
|
NCBI chr 7:8,733,056...8,738,543
Ensembl chr 7:8,082,364...8,098,914
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[hesperetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of SOCS3 protein] |
CTD |
PMID:33522063 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
hesperetin results in increased expression of SOD1 protein |
CTD |
PMID:19023542 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
hesperetin results in increased expression of SOD2 protein |
CTD |
PMID:19023542 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox18 |
SRY-box transcription factor 18 |
multiple interactions |
ISO |
hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SOX18 protein]; MIR410 mRNA affects the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SOX18 protein]] |
CTD |
PMID:32762101 |
|
NCBI chr 3:189,163,000...189,164,802
Ensembl chr 3:168,785,490...168,787,290
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
hesperetin analog affects the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:28428136 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:33522063 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[hesperetin analog co-treated with bisperoxovanadium analog] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; [hesperetin analog co-treated with bisperoxovanadium analog] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; hesperetin analog inhibits the reaction [bisperoxovanadium analog promotes the reaction [TGFB1 protein results in decreased expression of PTEN protein]]; hesperetin analog inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of MYC protein]; hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]; PTEN protein promotes the reaction [hesperetin analog inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]] |
CTD |
PMID:27818223 PMID:34922902 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression decreases expression |
ISO EXP |
[hesperetin analog co-treated with PPARG protein] affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; hesperetin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; hesperetin analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; hesperetin inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF protein]; hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; hesperetin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; MIR410 mRNA inhibits the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]] hesperetin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of TNF protein]; hesperetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; hesperetin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] hesperetin affects the expression of TNF protein hesperetin results in decreased expression of TNF mRNA |
CTD |
PMID:11123379 PMID:16934226 PMID:24871567 PMID:25345581 PMID:26546711 PMID:28428136 PMID:32762101 PMID:33522063 PMID:34922902 PMID:35567572 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [hesperetin results in increased expression of TP53 protein]; hesperetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] |
CTD |
PMID:15795422 PMID:37487865 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
affects binding |
ISO |
hesperetin binds to UQCRFS1 protein |
CTD |
PMID:37487865 |
|
NCBI chr17:34,173,787...34,190,952
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Utrn |
utrophin |
increases expression |
ISO |
hesperetin results in increased expression of UTRN mRNA |
CTD |
PMID:22028826 |
|
NCBI chr 1:8,541,061...9,044,487
Ensembl chr 1:6,722,594...7,224,313
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[bisphenol A diglycidyl ether co-treated with Hesperidin] inhibits the reaction [[Sodium Fluoride results in increased abundance of Fluorides] which results in increased activity of ACHE protein]; Hesperidin inhibits the reaction [[Sodium Fluoride results in increased abundance of Fluorides] which results in increased activity of ACHE protein] |
CTD |
PMID:32627286 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of AFP protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] |
CTD |
PMID:28935427 PMID:30779474 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of AKT1 protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in decreased activity of AKT1 protein] |
CTD |
PMID:30779474 PMID:35413380 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [Paclitaxel results in decreased expression of AKT2 mRNA] Hesperidin results in increased expression of AKT2 mRNA |
CTD |
PMID:36966900 |
|
NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions increases expression |
ISO |
[Hesperidin co-treated with Doxorubicin] results in increased expression of ALB protein Hesperidin results in increased expression of ALB protein |
CTD |
PMID:29481770 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of ATF6 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of ATF6 mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of ATF6 mRNA] Hesperidin results in decreased expression of ATF6 mRNA |
CTD |
PMID:34748272 PMID:35413380 PMID:36966900 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of BAX mRNA; Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BAX protein]]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BAX protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of BAX mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of BAX protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of BAX mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of BAX protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of BAX mRNA] Doxorubicin promotes the reaction [Hesperidin results in increased expression of BAX mRNA] |
CTD |
PMID:24954035 PMID:29481770 PMID:32050098 PMID:33908150 PMID:34748272 PMID:35413380 PMID:35921949 PMID:36966900 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[Hesperidin co-treated with Chlorpyrifos] results in decreased expression of BCL2 mRNA; Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BCL2 protein]]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BCL2 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Finasteride results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Paclitaxel results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in decreased expression of BCL2 mRNA] Hesperidin results in decreased expression of BCL2 mRNA Doxorubicin promotes the reaction [Hesperidin results in decreased expression of BCL2 mRNA] |
CTD |
PMID:22093918 PMID:24954035 PMID:29481770 PMID:30623541 PMID:32050098 PMID:33908150 PMID:34748272 PMID:35413380 PMID:35921949 PMID:36966900 PMID:38216069 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of BECN1 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of BECN1 protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of BECN1 protein] Hesperidin results in decreased expression of BECN1 protein |
CTD |
PMID:33908150 PMID:34748272 PMID:35413380 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
EXP |
Hesperidin results in increased expression of BMP2 mRNA |
CTD |
PMID:21820093 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases activity increases expression |
EXP ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of CASP3 mRNA; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [Finasteride results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of CASP3 mRNA]; Hesperidin promotes the reaction [Diethylnitrosamine results in increased expression of CASP3 protein] Hesperidin results in decreased expression of CASP3 protein [Hesperidin co-treated with Doxorubicin] results in increased activity of CASP3 protein; Doxorubicin promotes the reaction [Hesperidin results in increased expression of CASP3 mRNA] Hesperidin results in increased activity of CASP3 protein |
CTD |
PMID:22093918 PMID:29481770 PMID:30066062 PMID:30623541 PMID:30779474 PMID:33908150 PMID:34748272 PMID:35413380 PMID:35921949 PMID:36966900 PMID:38216069 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP9 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP9 protein] |
CTD |
PMID:22093918 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity increases activity |
EXP ISO |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [abamectin results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Acetic Acid results in increased activity of CAT protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CAT protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Finasteride results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of CAT protein]; Hesperidin inhibits the reaction [Paclitaxel results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in decreased activity of CAT protein] Hesperidin results in decreased activity of CAT protein Hesperidin results in increased activity of CAT protein Hesperidin inhibits the reaction [Doxorubicin results in increased activity of CAT protein] |
CTD |
PMID:22093918 PMID:29481770 PMID:30066062 PMID:30098279 PMID:30623541 PMID:30779474 PMID:31095933 PMID:32050098 PMID:33003968 PMID:33908150 PMID:34748272 PMID:35413380 PMID:36966900 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]; Hesperidin inhibits the reaction [Ethanol results in increased expression of CCL3 protein] |
CTD |
PMID:30368987 PMID:30811821 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CCND1 mRNA]; BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CCND1 protein]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CCND1 mRNA]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CCND1 protein] Hesperidin results in decreased expression of CCND1 mRNA; Hesperidin results in decreased expression of CCND1 protein |
CTD |
PMID:34984768 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of CDK2 protein] |
CTD |
PMID:30779474 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions decreases expression |
ISO |
BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CDK4 mRNA]; BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CDK4 protein]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CDK4 mRNA]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CDK4 protein] Hesperidin results in decreased expression of CDK4 mRNA; Hesperidin results in decreased expression of CDK4 protein |
CTD |
PMID:34984768 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression multiple interactions |
ISO |
Hesperidin results in decreased expression of CDK6 mRNA; Hesperidin results in decreased expression of CDK6 protein BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CDK6 mRNA]; BIX 02189 promotes the reaction [Hesperidin results in decreased expression of CDK6 protein]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CDK6 mRNA]; Hesperidin promotes the reaction [BIX 02189 results in decreased expression of CDK6 protein] |
CTD |
PMID:34984768 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
BIX 02189 promotes the reaction [Hesperidin results in increased expression of CDKN1A mRNA]; BIX 02189 promotes the reaction [Hesperidin results in increased expression of CDKN1A protein] Hesperidin results in increased expression of CDKN1A mRNA; Hesperidin results in increased expression of CDKN1A protein |
CTD |
PMID:34984768 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
BIX 02189 promotes the reaction [Hesperidin results in increased expression of CDKN1B mRNA]; BIX 02189 promotes the reaction [Hesperidin results in increased expression of CDKN1B protein] Hesperidin results in increased expression of CDKN1B mRNA; Hesperidin results in increased expression of CDKN1B protein |
CTD |
PMID:34984768 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] |
CTD |
PMID:17400256 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of EIF2AK3 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of EIF2AK3 mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of EIF2AK3 mRNA] Hesperidin results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:34748272 PMID:35413380 PMID:36966900 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of ERN1 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of ERN1 mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of ERN1 mRNA] |
CTD |
PMID:34748272 PMID:35413380 PMID:36966900 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased secretion of FABP9 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 2:93,499,136...93,503,267
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the activity of FASN protein] |
CTD |
PMID:16427799 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
G6pc3 |
glucose 6 phosphatase catalytic subunit 3 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Streptozocin results in decreased activity of G6PC3 protein] |
CTD |
PMID:31345080 |
|
NCBI chr10:87,647,149...87,651,385
Ensembl chr10:87,146,901...87,151,221
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity multiple interactions |
ISO EXP |
Hesperidin results in decreased activity of G6PD protein Hesperidin inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] Hesperidin affects the reaction [LEPR protein affects the activity of G6PD protein] |
CTD |
PMID:16427799 PMID:25130191 PMID:31345080 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of GCK mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr14:84,999,019...85,041,098
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
decreases activity multiple interactions |
ISO EXP |
Hesperidin results in decreased activity of GPT protein Hesperidin inhibits the reaction [Chlorpyrifos results in increased activity of GPT protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased activity of GPT protein] [Doxorubicin co-treated with Hesperidin] results in decreased activity of GPT protein |
CTD |
PMID:29481770 PMID:30066062 PMID:30779474 PMID:33908150 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased activity of GSR protein] |
CTD |
PMID:22093918 PMID:30098279 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] |
CTD |
PMID:22093918 PMID:30098279 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] promotes the reaction [YY1 protein binds to HDAC1 protein]] |
CTD |
PMID:34800614 |
|
NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the activity of HMGCR protein] |
CTD |
PMID:16427799 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of HMOX1 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of HMOX1 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HMOX1 protein]; Hesperidin inhibits the reaction [Paclitaxel results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:28935427 PMID:32050098 PMID:34748272 PMID:35921949 PMID:36966900 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of HSPA5 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of HSPA5 mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of HSPA5 mRNA] |
CTD |
PMID:34748272 PMID:35413380 PMID:36966900 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Glucose results in increased expression of ICAM1]; Hesperidin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:17400256 PMID:22074828 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Hesperidin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Hesperidin inhibits the reaction [TNF protein co-treated with and results in increased expression of IL1B protein co-treated with and results in increased expression of CXCL8 protein] Hesperidin inhibits the reaction [abamectin results in increased expression of IL1B mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of IL1B mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of IL1B protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of IL1B protein] Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:17400256 PMID:30066062 PMID:33908150 PMID:34748272 PMID:35413380 PMID:35921949 PMID:36966900 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Hesperidin promotes the reaction [Lipopolysaccharides results in increased expression of IL4 protein] |
CTD |
PMID:17400256 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Hesperidin results in decreased expression of IL6 protein [naringin co-treated with Hesperidin] results in decreased expression of IL6 protein; Hesperidin inhibits the reaction [abamectin results in increased expression of IL6 mRNA]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of IL6 protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of IL6 mRNA]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] |
CTD |
PMID:17400256 PMID:21820093 PMID:30066062 PMID:30623541 PMID:34748272 PMID:35921949 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of JAK2 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Lep |
leptin |
decreases expression multiple interactions |
EXP |
Hesperidin results in decreased expression of LEP protein [naringin co-treated with Hesperidin] results in decreased expression of LEP protein |
CTD |
PMID:21820093 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the abundance of Glucose]; Hesperidin affects the reaction [LEPR protein affects the activity of FASN protein]; Hesperidin affects the reaction [LEPR protein affects the activity of G6PD protein]; Hesperidin affects the reaction [LEPR protein affects the activity of HMGCR protein]; Hesperidin affects the reaction [LEPR protein affects the expression of GCK mRNA]; Hesperidin affects the reaction [LEPR protein affects the expression of PPARG protein]; Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A2 protein]; Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3A mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of MAP1LC3A mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of MAP1LC3A protein] |
CTD |
PMID:34748272 PMID:35413380 PMID:35921949 |
|
NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3B mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of MAP1LC3B mRNA]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of MAP1LC3B protein] |
CTD |
PMID:34748272 PMID:35413380 PMID:35921949 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases phosphorylation |
ISO |
Hesperidin results in decreased phosphorylation of MAP2K5 protein |
CTD |
PMID:34984768 |
|
NCBI chr 8:72,520,616...72,748,395
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAPK14 mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of MAPK14 protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of MAPK14 mRNA] |
CTD |
PMID:33908150 PMID:34748272 PMID:35921949 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
ISO |
BIX 02189 promotes the reaction [Hesperidin results in decreased phosphorylation of MAPK7 protein]; Hesperidin promotes the reaction [BIX 02189 results in decreased phosphorylation of MAPK7 protein]; Hesperidin results in decreased phosphorylation of and affects the localization of MAPK7 protein |
CTD |
PMID:34984768 |
|
NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,170,167...46,176,267
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Acetaldehyde results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19110045 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Acetaldehyde results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:19110045 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir126b |
microRNA 126b |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of MIR126B mRNA] |
CTD |
PMID:32050098 |
|
NCBI chr 3:29,813,174...29,813,246
|
|
G |
Mir181a2 |
microRNA 181a-2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased expression of MIR181A2 mRNA] |
CTD |
PMID:32050098 |
|
NCBI chr 3:43,025,563...43,025,679
Ensembl chr 3:22,615,845...22,615,961
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Paclitaxel results in increased expression of MMP2 mRNA] |
CTD |
PMID:35921949 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases secretion |
ISO EXP |
Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of and results in increased activity of MMP9 protein]; Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of MMP9 mRNA]; Hesperidin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA] Hesperidin inhibits the reaction [Paclitaxel results in increased expression of MMP9 mRNA] Hesperidin results in decreased secretion of MMP9 protein |
CTD |
PMID:19110045 PMID:20138977 PMID:35921949 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
EXP |
Hesperidin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] Hesperidin results in decreased activity of MPO protein |
CTD |
PMID:31095933 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Sodium Fluoride results in decreased expression of MTOR protein] |
CTD |
PMID:35413380 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of NFE2L2 mRNA]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of NFE2L2 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of NFE2L2 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of NFE2L2 protein]; Hesperidin inhibits the reaction [Paclitaxel results in decreased expression of NFE2L2 mRNA] Hesperidin results in increased expression of NFE2L2 mRNA |
CTD |
PMID:28935427 PMID:32050098 PMID:34748272 PMID:35921949 PMID:36966900 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of NFKB1 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NFKB1 mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of NFKB1 mRNA] Hesperidin results in increased expression of NFKB1 mRNA |
CTD |
PMID:22093918 PMID:34748272 PMID:35921949 PMID:36966900 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of NOS2 protein] Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:12512693 PMID:22093918 PMID:33908150 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of PARP1 mRNA; [Hesperidin co-treated with Chlorpyrifos] results in increased expression of PARP1 protein; Hesperidin inhibits the reaction [Ethanol results in increased activity of PARP1 protein] |
CTD |
PMID:30368987 PMID:33908150 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:28935427 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of PIK3R1 protein] |
CTD |
PMID:30779474 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of PPARG protein]]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of PPARG mRNA]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of PPARG protein]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of PPARG protein]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of PPARG protein] Hesperidin affects the reaction [LEPR protein affects the expression of PPARG protein] |
CTD |
PMID:16427799 PMID:24954035 PMID:28935427 PMID:30623541 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Dextran Sulfate results in decreased expression of PPARGC1A protein]; Hesperidin inhibits the reaction [Ethanol results in decreased expression of PPARGC1A protein] |
CTD |
PMID:30368987 PMID:30811821 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein] Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16101151 PMID:19110045 PMID:30098279 PMID:33908150 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Isoproterenol results in increased expression of RELA protein] |
CTD |
PMID:30623541 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sgpp2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SGPP2 mRNA] |
CTD |
PMID:30811821 |
|
NCBI chr 9:87,211,155...87,331,787
Ensembl chr 9:79,763,284...79,880,457
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 protein] |
CTD |
PMID:32050098 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] promotes the reaction [YY1 protein binds to SLC1A2 promoter]]; Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased expression of SLC1A2 protein] |
CTD |
PMID:34800614 |
|
NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A2 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 2:113,537,884...113,568,422
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SPHK1 protein] |
CTD |
PMID:30811821 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of STAT3 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Ethanol results in decreased expression of TFEB mRNA] |
CTD |
PMID:30368987 |
|
NCBI chr 9:20,696,440...20,752,265
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tnc |
tenascin C |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Ethanol results in increased expression of TNC protein] |
CTD |
PMID:30368987 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Hesperidin inhibits the reaction [TNF protein co-treated with and results in increased expression of IL1B protein co-treated with and results in increased expression of CXCL8 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Hesperidin results in decreased expression of TNF mRNA Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of TNF protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of TNF mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of TNF mRNA]; Hesperidin inhibits the reaction [Paclitaxel results in increased expression of TNF protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; Hesperidin inhibits the reaction [Sodium Fluoride results in increased expression of TNF protein] Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:17400256 PMID:28935427 PMID:30066062 PMID:30623541 PMID:33908150 PMID:34748272 PMID:35413380 PMID:35921949 PMID:36966900 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
increases expression |
ISO |
Hesperidin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:24633329 |
|
NCBI chr 5:167,904,377...167,909,052
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] |
CTD |
PMID:30066062 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
Hesperidin results in increased expression of TRADD mRNA |
CTD |
PMID:24633329 |
|
NCBI chr19:50,046,057...50,048,158
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
Hesperidin inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Hesperidin results in decreased expression of VCAM1 |
CTD |
PMID:17400256 PMID:30991044 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of VEGFA protein |
CTD |
PMID:33908150 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Yy1 |
YY1 transcription factor |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] promotes the reaction [YY1 protein binds to HDAC1 protein]]; Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] promotes the reaction [YY1 protein binds to SLC1A2 promoter]]; Hesperidin inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of and affects the localization of YY1 protein] |
CTD |
PMID:34800614 |
|
NCBI chr 6:133,471,615...133,500,875
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide affects the localization of AIFM1 protein] |
CTD |
PMID:29902531 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 protein] |
CTD |
PMID:29902531 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2L1 protein] |
CTD |
PMID:29902531 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:29902531 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] |
CTD |
PMID:29902531 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein] |
CTD |
PMID:31850465 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
homoeriodictyol results in decreased activity of CYP1A1 protein |
CTD |
PMID:10781868 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
homoeriodictyol results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
homoeriodictyol results in increased expression of GCLM mRNA |
CTD |
PMID:29902531 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
[homoeriodictyol co-treated with Glucose] results in increased secretion of GHRL protein |
CTD |
PMID:28834253 |
|
NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:31850465 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:31850465 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:31850465 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
homoeriodictyol results in increased expression of and results in increased localization of NFE2L2 protein; homoeriodictyol results in increased stability of and results in increased expression of and results in increased activity of NFE2L2 protein; NFE2L2 protein affects the reaction [homoeriodictyol results in increased expression of NQO1 protein] |
CTD |
PMID:29902531 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:31850465 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:31850465 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
homoeriodictyol results in increased expression of NQO1 mRNA NFE2L2 protein affects the reaction [homoeriodictyol results in increased expression of NQO1 protein] |
CTD |
PMID:29902531 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Hydrogen Peroxide results in increased cleavage of PARP1 protein] |
CTD |
PMID:29902531 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:31850465 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased localization of RELA protein] |
CTD |
PMID:31850465 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:31850465 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ar |
androgen receptor |
decreases localization multiple interactions decreases expression |
ISO |
isobavachin results in decreased localization of AR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [isobavachin results in decreased expression of and results in increased degradation of AR protein]; isobavachin binds to and results in decreased activity of AR protein; isobavachin results in decreased expression of and results in increased degradation of AR protein isobavachin results in decreased expression of AR protein |
CTD |
PMID:37019376 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased susceptibility to isobavachin] which results in increased activity of and results in increased cleavage of CASP1 protein |
CTD |
PMID:38969277 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased susceptibility to isobavachin] which results in increased expression of IL1B protein |
CTD |
PMID:38969277 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
isobavachin results in decreased expression of KLK3 mRNA; isobavachin results in decreased expression of KLK3 protein |
CTD |
PMID:37019376 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Pgr |
progesterone receptor |
multiple interactions increases expression |
ISO |
Fulvestrant inhibits the reaction [isobavachin results in increased expression of PGR mRNA]; Fulvestrant inhibits the reaction [isobavachin results in increased expression of PGR protein] isobavachin results in increased expression of PGR mRNA; isobavachin results in increased expression of PGR protein |
CTD |
PMID:16892383 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression multiple interactions |
ISO |
isobavachin results in increased expression of TFF1 mRNA Fulvestrant inhibits the reaction [isobavachin results in increased expression of TFF1 mRNA] |
CTD |
PMID:16892383 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597
|
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases activity |
ISO |
isoxanthohumol results in decreased activity of AKR1B10 protein |
CTD |
PMID:35065925 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
isoxanthohumol results in decreased activity of AKR1C3 protein |
CTD |
PMID:35065925 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions decreases activity |
ISO |
isoxanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; isoxanthohumol inhibits the reaction [CBR1 protein results in increased reduction of 2,3-hexanedione] isoxanthohumol results in decreased activity of CBR1 protein |
CTD |
PMID:30849340 PMID:35065925 |
|
NCBI chr11:46,346,405...46,348,815
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
isoxanthohumol results in increased expression of CYP1A2 mRNA |
CTD |
PMID:15672752 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity |
ISO |
isoxanthohumol results in increased activity of ESR1 protein |
CTD |
PMID:12623674 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
kurarinol results in decreased expression of BCL2L1 mRNA; kurarinol results in decreased expression of BCL2L1 protein kurarinol inhibits the reaction [STAT3 protein binds to BCL2L1 promoter] |
CTD |
PMID:24997323 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
kurarinol results in increased activity of CASP3 protein STAT3 protein inhibits the reaction [kurarinol results in increased activity of CASP3 protein] |
CTD |
PMID:24997323 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
kurarinol results in decreased expression of CCND1 protein |
CTD |
PMID:24997323 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
kurarinol results in decreased expression of MCL1 mRNA; kurarinol results in decreased expression of MCL1 protein |
CTD |
PMID:24997323 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
kurarinol inhibits the reaction [STAT3 protein binds to BCL2L1 promoter]; STAT3 protein inhibits the reaction [kurarinol results in increased activity of CASP3 protein] kurarinol results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:24997323 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
kuwanon-L results in decreased activity of PTPN1 protein |
CTD |
PMID:16356713 |
|
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA] liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of CCL2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
liquiritigenin results in increased expression of CXCL12 mRNA |
CTD |
PMID:28396216 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
liquiritigenin results in decreased activity of CYP19A1 protein |
CTD |
PMID:38403145 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
liquiritigenin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity |
ISO |
liquiritigenin results in increased activity of ESR1 protein |
CTD |
PMID:28396216 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity |
ISO |
liquiritigenin results in increased activity of ESR2 protein |
CTD |
PMID:25106122 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of GCLC mRNA] liquiritigenin results in increased expression of GCLC protein |
CTD |
PMID:29908794 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP |
liquiritigenin results in increased expression of GCLM protein liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of GCLM mRNA] |
CTD |
PMID:29908794 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased activity of GPT protein] |
CTD |
PMID:31589899 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of GSR mRNA]; liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of GSR protein] |
CTD |
PMID:29908794 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of HMOX1 mRNA] |
CTD |
PMID:29908794 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO EXP |
liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]; liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA]; liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]; liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritigenin inhibits the reaction [Monocrotaline affects the expression of HSPD1 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA] liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of IL6 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of MMP9 protein] |
CTD |
PMID:29908794 PMID:31589899 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased activity of MPO protein] |
CTD |
PMID:31589899 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
ISO EXP |
NFE2L2 gene mutant form results in decreased susceptibility to liquiritigenin liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:29908794 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA] liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO EXP |
liquiritigenin results in increased expression of NQO1 protein liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of NQO1 mRNA] |
CTD |
PMID:26473469 PMID:29908794 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
liquiritigenin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of RELA protein] |
CTD |
PMID:31589899 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of SQSTM1 protein] |
CTD |
PMID:29908794 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in increased expression of TLR4 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Trpm3 |
transient receptor potential cation channel, subfamily M, member 3 |
decreases activity |
ISO |
liquiritigenin results in decreased activity of TRPM3 protein |
CTD |
PMID:25361167 |
|
NCBI chr 1:229,099,741...229,984,172
Ensembl chr 1:219,672,892...220,560,717
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
liquiritigenin inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA] |
CTD |
PMID:23183181 |
|
NCBI chr X:109,006,410...109,066,389
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 mRNA]; liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr 7:111,377,338...111,390,940
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
multiple interactions |
EXP |
liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 mRNA]; liquiritigenin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr11:96,024,321...96,072,475
Ensembl chr11:82,519,999...82,568,156
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC3 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC4 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of CCL2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[brucine co-treated with liquiritin] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
liquiritin results in increased expression of GCLC protein liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLC mRNA] |
CTD |
PMID:29908794 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLM mRNA] liquiritin results in increased expression of GCLM protein |
CTD |
PMID:29908794 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of GPT protein] liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:31589899 PMID:36008890 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR protein] |
CTD |
PMID:29908794 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of HMOX1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of HMOX1 mRNA; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of HMOX1 protein] |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritin inhibits the reaction [Monocrotaline affects the expression of HSPD1 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:36008890 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA] liquiritin inhibits the reaction [Monocrotaline results in increased expression of IL6 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
liquiritin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of KEAP1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of MMP9 protein] |
CTD |
PMID:29908794 PMID:31589899 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of MPO protein] |
CTD |
PMID:31589899 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
ISO EXP |
NFE2L2 gene mutant form results in decreased susceptibility to liquiritin liquiritin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NFE2L2 protein] liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NQO1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of NQO1 mRNA |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:36008890 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of RELA protein] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] |
CTD |
PMID:31589899 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:36008890 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of SQSTM1 protein] |
CTD |
PMID:29908794 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of TLR4 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:36008890 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr 7:111,377,338...111,390,940
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr11:96,024,321...96,072,475
Ensembl chr11:82,519,999...82,568,156
|
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Naringenin increases expression of NR1H3 mRNA and protein in macrophages |
RGD |
PMID:29140707 |
RGD:401842389 |
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
naringin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[naringin co-treated with Dietary Fats] results in decreased expression of ACACA mRNA |
CTD |
PMID:22198281 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACE protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of ACE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of ACE protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of ACHE protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of ACHE protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACHE protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of ACHE protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of ACHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ACHE protein]; naringin inhibits the reaction [Caffeine results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of ACHE protein]; naringin inhibits the reaction [potassium bromate results in increased activity of ACHE protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein] naringin results in decreased expression of ACP5 mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ADA protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of ADA protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ADA protein]; naringin inhibits the reaction [Caffeine results in increased activity of ADA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ADA protein]; naringin inhibits the reaction [potassium bromate results in increased activity of ADA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:22198281 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA]; naringin inhibits the reaction [AGT protein results in increased secretion of Aldosterone] |
CTD |
PMID:22798349 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Acetaminophen results in decreased expression of AKR7A5 protein] |
CTD |
PMID:35166444 |
|
NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Methylprednisolone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; plerixafor inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein] naringin inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of AKT1 mRNA] |
CTD |
PMID:19810018 PMID:25773745 PMID:29510123 PMID:30878453 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
affects expression |
EXP |
naringin affects the expression of ANGPT1 mRNA |
CTD |
PMID:24880026 |
|
NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of ATF6 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAD mRNA] naringin inhibits the reaction [Dexamethasone results in increased phosphorylation of BAD protein] |
CTD |
PMID:21945202 PMID:30878453 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of BAX mRNA CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of BAX protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of BAX protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]] naringin inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [Acrylamide results in increased expression of BAX protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of BAX mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of BAX protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:21945202 PMID:22847135 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of BCHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of BCHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of BCHE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA] naringin results in decreased expression of BCL2 protein CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]] naringin inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:21945202 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression increases secretion multiple interactions |
ISO EXP |
naringin results in increased expression of BGLAP mRNA; naringin results in increased expression of BGLAP protein naringin results in increased secretion of BGLAP protein fulvestrant inhibits the reaction [naringin results in increased secretion of BGLAP protein] |
CTD |
PMID:18495116 PMID:21741227 PMID:23596885 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions decreases expression increases secretion increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter]; naringin promotes the reaction [JUN protein binds to BMP2 promoter] naringin results in decreased expression of BMP2 mRNA fulvestrant inhibits the reaction [naringin results in increased secretion of BMP2 protein] naringin results in increased expression of BMP2 mRNA; naringin results in increased expression of BMP2 protein |
CTD |
PMID:18495116 PMID:21820093 PMID:23596885 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp3 |
bone morphogenetic protein 3 |
decreases expression |
ISO |
naringin results in decreased expression of BMP3 mRNA |
CTD |
PMID:18495116 |
|
NCBI chr14:11,012,564...11,041,282
Ensembl chr14:10,712,489...10,737,153
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
naringin results in increased expression of BMP4 mRNA |
CTD |
PMID:24915843 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 4:32,615,955...32,691,075
Ensembl chr 4:31,661,273...31,736,392
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of CASP3 mRNA naringin inhibits the reaction [Acetaminophen results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein modified form]; naringin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; naringin inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of CASP3 protein] naringin inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]; naringin inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of CASP3 protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; rottlerin inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:21945202 PMID:22847135 PMID:25773745 PMID:26612654 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of CASP9 mRNA [bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of CASP9 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP9 protein]; naringin inhibits the reaction [bisphenol A results in increased expression of CASP9 protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of CASP9 protein] |
CTD |
PMID:22847135 PMID:25773745 PMID:32172062 PMID:32428650 PMID:32810514 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of CAT protein]; naringin inhibits the reaction [Ferric Compounds results in decreased activity of CAT protein]; naringin inhibits the reaction [Nanotubes, Carbon results in decreased activity of CAT protein] naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased activity of CAT protein]; naringin inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of CAT protein]; naringin inhibits the reaction [Oxaliplatin results in decreased activity of CAT protein] |
CTD |
PMID:20950607 PMID:21345335 PMID:21945202 PMID:22198281 PMID:25773745 PMID:26120027 PMID:26612654 PMID:29658312 PMID:33992719 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA] |
CTD |
PMID:22965302 PMID:33992719 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL3 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:22965302 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] |
CTD |
PMID:21500970 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions increases expression |
ISO EXP |
naringin results in decreased expression of CCND1 protein naringin inhibits the reaction [Dexamethasone results in increased expression of CCND1 mRNA] naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCND1 protein] naringin results in increased expression of CCND1 mRNA |
CTD |
PMID:18296682 PMID:18951945 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO EXP |
naringin results in decreased expression of CCNE1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] naringin results in increased expression of CDKN1A mRNA; naringin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
multiple interactions |
ISO |
CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of CHAC2 protein] |
CTD |
PMID:35166444 PMID:35179299 |
|
NCBI chr14:108,921,669...108,929,215
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
naringin results in increased expression of COL1A1 mRNA |
CTD |
PMID:21741227 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Dietary Fats co-treated with naringin] results in decreased expression of CPT1A mRNA |
CTD |
PMID:22198281 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr18:56,834,152...56,860,804
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
naringin results in increased expression of CTNNB1 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:24915843 PMID:26482937 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of CTSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] naringin results in decreased expression of CTSK mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
naringin results in increased expression of CXCL12 protein |
CTD |
PMID:29510123 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression |
ISO |
naringin affects the expression of CXCL2 mRNA |
CTD |
PMID:25117567 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
naringin results in increased expression of CXCR4 protein |
CTD |
PMID:29510123 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein] |
CTD |
PMID:25391245 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of CYCS protein] |
CTD |
PMID:28422390 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:22798349 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
naringin results in decreased activity of CYP1A1 protein |
CTD |
PMID:21053930 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
naringin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
naringin binds to and results in decreased activity of CYP1B1 protein |
CTD |
PMID:21053930 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO |
naringin results in decreased activity of CYP3A4 protein naringin inhibits the reaction [CYP3A4 protein affects the metabolism of Verapamil] |
CTD |
PMID:16013069 PMID:21053930 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases activity |
ISO |
naringin results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 2:25,320,895...25,346,004
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]] |
CTD |
PMID:26482937 |
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein]; naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22766066 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of ERN1 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR1 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
naringin results in increased expression of FADD mRNA |
CTD |
PMID:22847135 |
|
NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
naringin results in increased expression of FAS mRNA |
CTD |
PMID:22847135 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter] naringin results in increased expression of FOS mRNA |
CTD |
PMID:18495116 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of FSHB protein] |
CTD |
PMID:36598108 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of G6PC1 mRNA]; naringin inhibits the reaction [Dietary Fats results in increased expression of G6PC1 mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [nickel sulfate results in decreased activity of G6PD protein] naringin affects the reaction [LEPR protein affects the activity of G6PD protein] |
CTD |
PMID:16427799 PMID:20950607 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of GCK mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr14:84,999,019...85,041,098
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of GCLC mRNA; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of GCLC protein]; rottlerin inhibits the reaction [naringin results in increased expression of GCLC protein] naringin results in increased expression of GCLC mRNA; naringin results in increased expression of GCLC protein |
CTD |
PMID:22871521 PMID:25773745 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Acetaminophen results in increased secretion of GOT1 protein] |
CTD |
PMID:35166444 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; naringin inhibits the reaction [Oxaliplatin results in increased activity of GPT protein]; naringin inhibits the reaction [sodium arsenite results in increased expression of GPT protein] naringin inhibits the reaction [Acetaminophen results in increased secretion of GPT protein]; naringin inhibits the reaction [Doxorubicin results in increased expression of GPT protein] |
CTD |
PMID:27174133 PMID:33992719 PMID:35166444 PMID:36811345 PMID:38037725 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases activity |
ISO |
naringin results in increased activity of GPX1 protein |
CTD |
PMID:23603004 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of GSR protein] naringin inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:20950607 PMID:21945202 PMID:23650045 PMID:33992719 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
naringin results in increased expression of GSTP1 mRNA [naringin co-treated with 3-nitropropionic acid] results in increased expression of GSTP1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr12:32,337,281...32,350,838
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein] naringin affects the reaction [LEPR protein affects the activity of HMGCR protein] |
CTD |
PMID:16427799 PMID:16906524 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; naringin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 protein]; naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]] naringin results in increased expression of HMOX1 mRNA; naringin results in increased expression of HMOX1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of HMOX1 mRNA; naringin inhibits the reaction [Oxaliplatin results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [sodium arsenite results in decreased expression of HMOX1 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [naringin results in increased expression of HMOX1 protein] naringin results in increased activity of HMOX1 protein |
CTD |
PMID:22871521 PMID:23603004 PMID:25773745 PMID:27174133 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions increases activity |
ISO EXP |
HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of HRAS protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of HSPA5 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [Glucose results in increased expression of ICAM1]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] naringin inhibits the reaction [Acetaminophen results in increased expression of ICAM1 mRNA] naringin affects the expression of ICAM1 mRNA |
CTD |
PMID:22074828 PMID:25117567 PMID:25391245 PMID:35166444 PMID:35179299 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifna1 |
interferon, alpha 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 5:108,143,240...108,143,809
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] naringin affects the expression of IFNG mRNA |
CTD |
PMID:16945185 PMID:21500970 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression multiple interactions increases expression |
EXP ISO |
naringin affects the expression of IGF1 mRNA naringin inhibits the reaction [Dexamethasone results in increased expression of IGF1 mRNA] naringin results in increased expression of IGF1 mRNA fulvestrant inhibits the reaction [naringin results in increased expression of IGF1 mRNA] |
CTD |
PMID:23596885 PMID:24880026 PMID:30878453 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il10 |
interleukin 10 |
multiple interactions affects expression |
EXP ISO |
naringin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 protein] naringin affects the expression of IL10 protein |
CTD |
PMID:22985397 PMID:25117567 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
affects expression multiple interactions |
EXP ISO |
naringin affects the expression of IL1B mRNA [bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA]; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of IL1B protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of IL1B protein]; naringin inhibits the reaction [Acrylamide results in increased expression of IL1B protein]; naringin inhibits the reaction [bisphenol A results in increased expression of IL1B protein]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of IL1B protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of IL1B mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B protein] naringin inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; naringin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA] |
CTD |
PMID:24131540 PMID:24880026 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 PMID:33992719 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il2 |
interleukin 2 |
affects expression |
ISO |
naringin affects the expression of IL2 protein |
CTD |
PMID:25117567 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
affects expression |
ISO |
naringin affects the expression of IL4 protein |
CTD |
PMID:25117567 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects expression multiple interactions decreases expression |
EXP ISO |
naringin affects the expression of IL6 mRNA [naringin co-treated with Hesperidin] results in decreased expression of IL6 protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Acrylamide results in increased expression of IL6 protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein] naringin results in decreased expression of IL6 protein naringin affects the expression of IL6 protein naringin inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 protein] |
CTD |
PMID:16137700 PMID:19810018 PMID:21820093 PMID:24131540 PMID:24880026 PMID:25117567 PMID:30130594 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; naringin promotes the reaction [Glucose results in increased secretion of INS1 protein] naringin affects the expression of INS1 protein |
CTD |
PMID:24880026 PMID:29658312 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:22198281 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]; naringin promotes the reaction [JUN protein binds to BMP2 promoter]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]] naringin results in increased expression of JUN mRNA |
CTD |
PMID:18495116 PMID:35166444 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Doxorubicin results in decreased expression of KEAP1 protein] |
CTD |
PMID:36811345 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein] |
CTD |
PMID:16906524 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:17188415 |
|
NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lep |
leptin |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Dietary Fats results in increased expression of LEP protein] [naringin co-treated with Hesperidin] results in decreased expression of LEP protein; naringin inhibits the reaction [Glucose results in increased expression of LEP protein] |
CTD |
PMID:21820093 PMID:22198281 PMID:24399619 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO EXP |
naringin affects the reaction [LEPR protein affects the abundance of Glucose]; naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin affects the reaction [LEPR protein affects the activity of G6PD protein]; naringin affects the reaction [LEPR protein affects the activity of HMGCR protein]; naringin affects the reaction [LEPR protein affects the expression of G6PC1 mRNA]; naringin affects the reaction [LEPR protein affects the expression of GCK mRNA]; naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA]; naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] naringin inhibits the reaction [Glucose results in increased expression of LEPR protein] |
CTD |
PMID:16427799 PMID:24399619 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of LHB protein] |
CTD |
PMID:36598108 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] |
CTD |
PMID:16906524 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
EXP |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of MAOA protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of MAOA protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of MAOA protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of MAOA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of MAOA protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin results in decreased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK10 protein] |
CTD |
PMID:22198281 |
|
NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in increased expression of MAPK14 mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in decreased phosphorylation of MAPK3 protein naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:22198281 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:22198281 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir126a |
microRNA 126a |
multiple interactions increases expression |
ISO |
MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA] naringin results in increased expression of MIR126 mRNA |
CTD |
PMID:24975661 |
|
NCBI chr 3:29,813,150...29,813,267
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
naringin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:26721195 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Paraquat results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of MMP9 protein] naringin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; naringin results in decreased expression of and results in decreased activity of MMP9 protein naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MMP9 protein] |
CTD |
PMID:19810018 PMID:22985397 PMID:23603004 PMID:25866363 PMID:26721195 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
naringin inhibits the reaction [Tobacco Smoke Pollution results in increased activity of MPO protein] |
CTD |
PMID:22985397 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of MT3 protein] |
CTD |
PMID:28422390 |
|
NCBI chr19:10,854,676...10,856,080
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein] |
CTD |
PMID:19810018 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 PMID:31301536 |
|
NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; [naringin co-treated with 3-nitropropionic acid] affects the localization of NFE2L2 protein; naringin inhibits the reaction [Oxaliplatin results in decreased expression of NFE2L2 mRNA]; naringin inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] affects the localization of NFE2L2 protein]; rottlerin inhibits the reaction [naringin affects the localization of NFE2L2 protein] CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]; naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:22871521 PMID:25773745 PMID:27174133 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cisplatin results in increased expression of NFKB1 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:26120027 PMID:26612654 PMID:38037725 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects degradation multiple interactions |
ISO |
naringin affects the degradation of NFKBIA protein naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:21835177 PMID:25117567 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects expression multiple interactions |
ISO EXP |
naringin affects the expression of NOS2 mRNA naringin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] naringin inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of NOS2 mRNA] |
CTD |
PMID:16137700 PMID:22871521 PMID:25117567 PMID:26612654 PMID:38037725 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein] |
CTD |
PMID:25391245 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP |
[naringin co-treated with 3-nitropropionic acid] results in increased expression of NQO1 mRNA naringin results in increased expression of NQO1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of OGDH protein] |
CTD |
PMID:17994577 |
|
NCBI chr14:85,363,949...85,431,405
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pde5a |
phosphodiesterase 5A |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of PDE5A protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of PDE5A protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of PDE5A protein]; naringin inhibits the reaction [Caffeine results in increased activity of PDE5A protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of PDE5A protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein]; naringin inhibits the reaction [potassium bromate results in increased activity of PDE5A protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3CA mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3R1 mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO EXP |
naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA] |
CTD |
PMID:16427799 PMID:22198281 PMID:30130594 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
naringin inhibits the reaction [Ethanol results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:18793633 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkcd |
protein kinase C, delta |
increases phosphorylation multiple interactions |
EXP |
naringin results in increased phosphorylation of PRKCD protein rottlerin inhibits the reaction [naringin results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:25773745 |
|
NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression multiple interactions |
ISO EXP |
naringin affects the expression of PTGS2 mRNA; naringin affects the expression of PTGS2 protein naringin inhibits the reaction [Acetaminophen results in increased expression of PTGS2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of PTGS2 protein]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] naringin inhibits the reaction [3-nitropropionic acid results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16137700 PMID:22871521 PMID:25117567 PMID:35166444 PMID:35179299 PMID:36811345 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions increases activity increases phosphorylation |
ISO EXP |
RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein]; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of RAF1 protein naringin results in increased phosphorylation of RAF1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein affects the localization of RELA protein] naringin affects the expression of and affects the activity of RELA protein; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:21500970 PMID:22766066 PMID:22965302 PMID:25117567 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
naringin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [Okadaic Acid results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:15342961 PMID:19810018 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of RUNX2 mRNA naringin inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein] DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]]; naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of RUNX2 mRNA] |
CTD |
PMID:21741227 PMID:23596885 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [Ethanol results in increased expression of SIRT1 mRNA] naringin inhibits the reaction [Doxorubicin results in decreased expression of SIRT1 protein]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]] |
CTD |
PMID:18793633 PMID:36811345 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 2:113,537,884...113,568,422
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
naringin inhibits the reaction [SLCO1A2 protein alternative form results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased transport of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quercetin]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quinine] |
CTD |
PMID:24947867 PMID:25466967 PMID:27504015 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
naringin inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein]; naringin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea] |
CTD |
PMID:21256917 PMID:22394605 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
naringin inhibits the reaction [sodium arsenite results in increased expression of SMAD3 mRNA] |
CTD |
PMID:27174133 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; naringin inhibits the reaction [Ferric Compounds results in decreased activity of SOD2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]] |
CTD |
PMID:21345335 PMID:35166444 PMID:35179299 PMID:36811345 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression multiple interactions |
EXP ISO |
naringin results in increased expression of SP7 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SP7 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of SP7 mRNA] |
CTD |
PMID:23596885 PMID:26482937 |
|
NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spn |
sialophorin |
multiple interactions increases expression decreases expression |
EXP |
[bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of SPN protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of SPN protein]; naringin inhibits the reaction [bisphenol A results in increased expression of SPN protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of SPN protein] naringin results in increased expression of SPN protein naringin results in decreased expression of SPN protein |
CTD |
PMID:32172062 PMID:32428650 |
|
NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression increases secretion multiple interactions |
ISO EXP |
naringin results in increased expression of SPP1 mRNA; naringin results in increased expression of SPP1 protein naringin results in increased secretion of SPP1 protein fulvestrant inhibits the reaction [naringin results in increased secretion of SPP1 protein] |
CTD |
PMID:18495116 PMID:23596885 PMID:24915843 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of STAR mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
affects expression |
ISO |
naringin affects the expression of STAT3 mRNA; naringin affects the expression of STAT3 protein |
CTD |
PMID:25117567 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] naringin inhibits the reaction [Cyclophosphamide results in increased expression of TGFB1 mRNA]; naringin inhibits the reaction [sodium arsenite results in increased expression of TGFB1 mRNA] naringin affects the expression of TGFB1 mRNA |
CTD |
PMID:23603004 PMID:25117567 PMID:27174133 PMID:33992719 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 protein] |
CTD |
PMID:23603004 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; naringin inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; naringin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; naringin inhibits the reaction [Paraquat results in increased expression of TNF mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TNF protein]; naringin inhibits the reaction [Acrylamide results in increased expression of TNF protein]; naringin inhibits the reaction [bisphenol A results in increased expression of TNF protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TNF protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TNF protein] naringin affects the expression of TNF protein naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin affects the expression of TNF mRNA |
CTD |
PMID:16137700 PMID:19810018 PMID:21500970 PMID:22198281 PMID:22871521 PMID:22985397 PMID:23603004 PMID:24131540 PMID:24880026 PMID:25117567 PMID:25391245 PMID:26120027 PMID:26612654 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
decreases expression |
ISO |
naringin results in decreased expression of TNFRSF11A mRNA |
CTD |
PMID:24376342 |
|
NCBI chr13:22,442,930...22,501,257
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of TNFRSF11B protein] |
CTD |
PMID:30878453 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA]; naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21835177 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:17188415 |
|
NCBI chr13:49,819,123...49,837,125
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions decreases expression |
ISO EXP |
naringin results in increased expression of TP53 mRNA naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]] naringin results in decreased expression of TP53 protein [bisphenol A co-treated with naringin] results in decreased expression of TP53 protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of TP53 protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TP53 protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TP53 protein]; naringin inhibits the reaction [Acrylamide results in increased expression of TP53 mRNA]; naringin inhibits the reaction [bisphenol A results in increased expression of TP53 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TP53 protein] |
CTD |
PMID:22847135 PMID:26120027 PMID:26612654 PMID:32172062 PMID:32428650 PMID:32810514 PMID:36598108 PMID:36811345 More...
|
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP protein] |
CTD |
PMID:24131540 |
|
NCBI chr18:24,723,990...24,728,419
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of UCP2 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin results in decreased expression of VCAM1 mRNA; naringin results in decreased expression of VCAM1 protein |
CTD |
PMID:24975661 PMID:25391245 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfc |
vascular endothelial growth factor C |
affects expression |
EXP |
naringin affects the expression of VEGFC mRNA |
CTD |
PMID:24880026 |
|
NCBI chr16:44,445,293...44,560,887
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[astilbin co-treated with Cisplatin] results in increased expression of AKR1C1 mRNA |
CTD |
PMID:29471006 |
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:29471006 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:29471006 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in decreased expression of GCLC mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin results in increased expression of GCLM mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of IL6 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin affects the localization of NFE2L2 protein] astilbin promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29471006 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
astilbin promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:29471006 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:29471006 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of TNF protein] astilbin promotes the reaction [Cisplatin results in increased expression of TNF mRNA] |
CTD |
PMID:29471006 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
astilbin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] |
CTD |
PMID:29471006 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO |
neoeriocitrin inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of BGLAP mRNA] neoeriocitrin results in increased expression of BGLAP mRNA |
CTD |
PMID:21741227 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO |
neoeriocitrin inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of COL1A1 mRNA] neoeriocitrin results in increased expression of COL1A1 mRNA |
CTD |
PMID:21741227 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
neoeriocitrin results in increased expression of RUNX2 mRNA |
CTD |
PMID:21741227 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:16,167,482...16,492,167
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of AHR mRNA]; pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of AHR protein] |
CTD |
PMID:33393179 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
pinocembrin results in decreased activity of CYP19A1 protein |
CTD |
PMID:38403145 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; pinocembrin promotes the reaction [Dasatinib inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] |
CTD |
PMID:33393179 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
pinocembrin results in decreased activity of CYP1A2 protein |
CTD |
PMID:29753067 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects activity |
ISO |
pinocembrin affects the activity of CYP3A4 protein |
CTD |
PMID:29753067 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased activity of GPT protein] |
CTD |
PMID:33393179 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of H2AX protein] |
CTD |
PMID:33393179 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK1 protein]; pinocembrin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK1 protein]; pinocembrin promotes the reaction [Dasatinib inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:18295389 PMID:33393179 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK3 protein]; pinocembrin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK3 protein]; pinocembrin promotes the reaction [Dasatinib inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18295389 PMID:33393179 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of SRC protein]; pinocembrin promotes the reaction [Dasatinib inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of SRC protein]] |
CTD |
PMID:33393179 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO EXP |
SULT1A1 protein results in increased sulfation of pinocembrin |
CTD |
PMID:11181495 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Ethanol results in increased activity of TGM2 protein]; pinocembrin inhibits the reaction [Ethanol results in increased expression of TGM2 mRNA] |
CTD |
PMID:18295389 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of TP53BP1 protein] pinocembrin inhibits the reaction [Benzo(a)pyrene results in increased expression of TRP53BP1 protein] |
CTD |
PMID:33393179 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of AARS1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr19:55,906,694...55,930,499
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity decreases response to substance |
ISO |
[pinostrobin results in decreased activity of ABCB1 protein] which results in decreased export of calcein AM; pinostrobin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Docetaxel]; pinostrobin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; pinostrobin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] ABCB1 protein results in decreased susceptibility to pinostrobin |
CTD |
PMID:37259354 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acvr1 |
activin A receptor type 1 |
increases expression |
ISO |
pinostrobin results in increased expression of ACVR1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:63,387,378...63,506,980
Ensembl chr 3:42,978,561...43,098,241
|
|
G |
Ahctf1 |
AT hook containing transcription factor 1 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of AHCTF1 protein |
CTD |
PMID:37164308 |
|
NCBI chr13:94,013,894...94,068,348
Ensembl chr13:91,481,936...91,536,391
|
|
G |
Aifm3 |
AIF family member 3 |
increases expression |
ISO |
pinostrobin results in increased expression of AIFM3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr11:97,009,100...97,030,601
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Arel1 |
apoptosis resistant E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of AREL1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 6:110,296,072...110,348,751
Ensembl chr 6:104,564,986...104,617,628
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
pinostrobin results in increased expression of ASNS mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
pinostrobin results in increased expression of ATM mRNA; pinostrobin results in increased expression of ATM protein |
CTD |
PMID:37208425 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
ISO |
pinostrobin results in increased expression of ATP5F1A mRNA |
CTD |
PMID:37777166 |
|
NCBI chr18:73,567,537...73,575,473
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
pinostrobin results in increased expression of AXL mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
pinostrobin results in increased expression of BAD mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
pinostrobin results in increased expression of BAK1 mRNA |
CTD |
PMID:37164308 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
pinostrobin results in increased expression of BAX mRNA; pinostrobin results in increased expression of BAX protein pinostrobin inhibits the reaction [Azoxymethane results in decreased expression of BAX protein]; pinostrobin inhibits the reaction [Cadmium results in increased expression of BAX mRNA] |
CTD |
PMID:37208425 PMID:37342552 PMID:37777166 PMID:38078205 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
pinostrobin results in increased expression of BBC3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
pinostrobin results in decreased expression of BCL2 protein pinostrobin inhibits the reaction [Azoxymethane results in increased expression of BCL2 protein]; pinostrobin inhibits the reaction [Cadmium results in decreased expression of BCL2 mRNA] |
CTD |
PMID:37342552 PMID:37777166 PMID:38078205 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
pinostrobin results in increased expression of BCL2L11 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases expression |
ISO |
pinostrobin results in decreased expression of BCL2L2 mRNA |
CTD |
PMID:37164308 |
|
NCBI chr15:32,326,686...32,337,834
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
pinostrobin results in increased expression of BMF mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
increases expression |
ISO |
pinostrobin results in increased expression of CALHM2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:255,963,661...255,969,387
Ensembl chr 1:246,022,324...246,028,218
|
|
G |
Capn3 |
calpain 3 |
increases expression |
ISO |
pinostrobin results in increased expression of CAPN3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:127,860,002...127,913,677
Ensembl chr 3:107,407,850...107,457,858
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
pinostrobin results in increased expression of CASP3 mRNA; pinostrobin results in increased expression of CASP3 protein [MIR410 mRNA co-treated with pinostrobin] results in increased expression of CASP3 mRNA; [MIR410 mRNA co-treated with pinostrobin] results in increased expression of CASP3 protein pinostrobin inhibits the reaction [Cadmium results in increased expression of CASP3 mRNA]; pinostrobin inhibits the reaction [Methotrexate results in increased activity of CASP3 protein] |
CTD |
PMID:37164308 PMID:37208425 PMID:37342552 PMID:37866152 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
pinostrobin results in increased expression of CASP8 mRNA |
CTD |
PMID:37208425 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
pinostrobin results in increased expression of CASP9 mRNA |
CTD |
PMID:37208425 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in decreased activity of CAT protein]; pinostrobin inhibits the reaction [Methotrexate results in decreased activity of CAT protein] |
CTD |
PMID:37342552 PMID:37866152 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbs |
cystathionine beta synthase |
increases expression |
ISO |
pinostrobin results in increased expression of CBS mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
pinostrobin results in decreased expression of CCNE1 protein |
CTD |
PMID:37777166 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
pinostrobin results in increased expression of CD14 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd70 |
Cd70 molecule |
increases expression |
ISO |
pinostrobin results in increased expression of CD70 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 9:2,093,540...2,096,692
Ensembl chr 9:2,006,563...2,009,715
|
|
G |
Cdc40 |
cell division cycle 40 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of CDC40 protein |
CTD |
PMID:37164308 |
|
NCBI chr20:45,855,739...45,908,239
Ensembl chr20:44,273,089...44,325,358
|
|
G |
Cdh1 |
cadherin 1 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of CDH1 protein |
CTD |
PMID:37164308 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
pinostrobin results in increased expression of CDKN1A mRNA; pinostrobin results in increased expression of CDKN1A protein |
CTD |
PMID:37777166 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
pinostrobin results in increased expression of CDKN1B protein |
CTD |
PMID:37777166 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
pinostrobin results in increased expression of CEBPB mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of CHAC1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
increases expression |
ISO |
pinostrobin results in increased expression of CIDEB mRNA |
CTD |
PMID:37777166 |
|
NCBI chr15:33,222,135...33,226,407
Ensembl chr15:29,252,213...29,256,605
|
|
G |
Cldn7 |
claudin 7 |
increases expression |
ISO |
pinostrobin results in increased expression of CLDN7 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:55,188,670...55,190,871
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
decreases expression |
ISO |
pinostrobin results in decreased expression of CRELD2 protein |
CTD |
PMID:37164308 |
|
NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
pinostrobin results in increased expression of CTH mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression |
ISO |
pinostrobin inhibits the reaction [MIR410 mRNA results in increased expression of CTNNB1 mRNA]; pinostrobin inhibits the reaction [MIR410 mRNA results in increased expression of CTNNB1 protein] pinostrobin results in decreased expression of CTNNB1 mRNA; pinostrobin results in decreased expression of CTNNB1 protein |
CTD |
PMID:37164308 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
pinostrobin results in increased expression of CXCR4 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Dcps |
decapping enzyme, scavenger |
increases expression |
ISO |
pinostrobin results in increased expression of DCPS mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 8:41,729,507...41,782,222
Ensembl chr 8:33,415,671...33,524,389
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
pinostrobin results in increased expression of DDIT3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
pinostrobin results in increased expression of DDIT4 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dnase1 |
deoxyribonuclease 1 |
increases expression |
ISO |
pinostrobin results in increased expression of DNASE1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:12,005,305...12,030,615
Ensembl chr10:11,498,931...11,501,869
|
|
G |
Dnase2 |
deoxyribonuclease 2, lysosomal |
increases expression |
ISO |
pinostrobin results in increased expression of DNASE2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr19:40,149,505...40,152,225
Ensembl chr19:23,244,664...23,247,376
|
|
G |
Doc2b |
double C2 domain beta |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of DOC2B protein |
CTD |
PMID:37164308 |
|
NCBI chr10:61,126,295...61,151,533
Ensembl chr10:60,628,029...60,653,267
|
|
G |
Elmo1 |
engulfment and cell motility 1 |
increases expression |
ISO |
pinostrobin results in increased expression of ELMO1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr17:48,982,188...49,518,525
Ensembl chr17:44,286,485...44,822,788
|
|
G |
Erc1 |
ELKS/RAB6-interacting/CAST family member 1 |
increases expression |
ISO |
pinostrobin results in increased expression of ERC1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:154,435,936...154,727,987
Ensembl chr 4:152,767,419...153,055,639
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
increases expression |
ISO |
pinostrobin results in increased expression of ERCC2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
increases expression |
ISO |
pinostrobin results in increased expression of ETV6 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:168,580,405...168,819,817
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Fank1 |
fibronectin type III and ankyrin repeat domains 1 |
increases expression |
ISO |
pinostrobin results in increased expression of FANK1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:188,577,575...188,685,504
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
pinostrobin results in increased expression of FAS mRNA |
CTD |
PMID:37208425 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbh1 |
F-box DNA helicase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of FBH1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr17:71,659,351...71,697,431
Ensembl chr17:66,749,534...66,787,590
|
|
G |
Fcmr |
Fc mu receptor |
increases expression |
ISO |
pinostrobin results in increased expression of FCMR mRNA |
CTD |
PMID:37777166 |
|
NCBI chr13:44,889,628...44,903,926
Ensembl chr13:42,337,414...42,351,653
|
|
G |
Fer1l4 |
fer-1-like family member 4 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of FER1L4 protein |
CTD |
PMID:37164308 |
|
NCBI chr 3:164,996,183...165,031,719
Ensembl chr 3:144,536,099...144,571,634
|
|
G |
Flcn |
folliculin |
increases expression |
ISO |
pinostrobin results in increased expression of FLCN mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:45,088,164...45,107,581
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
decreases phosphorylation |
ISO |
pinostrobin results in decreased phosphorylation of FMO5 protein |
CTD |
PMID:37164308 |
|
NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:185,222,204...185,249,693
|
|
G |
Foxa1 |
forkhead box A1 |
increases expression |
ISO |
pinostrobin results in increased expression of FOXA1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 6:80,838,380...80,871,195
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases expression |
ISO |
pinostrobin results in increased expression of and affects the localization of FOXO3 protein pinostrobin results in increased expression of FOXO3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Methotrexate results in increased expression of FSHB protein] |
CTD |
PMID:37866152 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
pinostrobin results in increased expression of FYN mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:44,322,635...44,514,498
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
pinostrobin results in increased expression of GADD45A mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Glb1 |
galactosidase, beta 1 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of GLB1 protein |
CTD |
PMID:37164308 |
|
NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Grina |
glutamate ionotropic receptor NMDA type subunit associated protein 1 |
increases expression |
ISO |
pinostrobin results in increased expression of GRINA mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:107,962,207...107,965,366
|
|
G |
Grn |
granulin precursor |
increases expression |
ISO |
pinostrobin results in increased expression of GRN mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in decreased activity of GSR protein] |
CTD |
PMID:37342552 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in increased expression of HAVCR1 protein] |
CTD |
PMID:37342552 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
increases expression |
ISO |
pinostrobin results in increased expression of HIP1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr12:26,769,868...26,904,367
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of HMOX1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsh2d |
hematopoietic SH2 domain containing |
increases expression |
ISO |
pinostrobin results in increased expression of HSH2D mRNA |
CTD |
PMID:37777166 |
|
NCBI chr16:17,664,548...17,686,976
Ensembl chr16:17,635,322...17,647,991
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
pinostrobin results in increased expression of ID3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Azoxymethane results in decreased expression of IL10 protein] |
CTD |
PMID:38078205 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in increased expression of IL1B protein]; pinostrobin inhibits the reaction [Methotrexate results in increased expression of IL1B protein] |
CTD |
PMID:37342552 PMID:37866152 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Azoxymethane results in increased expression of IL6 protein]; pinostrobin inhibits the reaction [Cadmium results in increased expression of IL6 protein]; pinostrobin inhibits the reaction [Methotrexate results in increased expression of IL6 protein] |
CTD |
PMID:37342552 PMID:37866152 PMID:38078205 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ing4 |
inhibitor of growth family, member 4 |
increases expression |
ISO |
pinostrobin results in increased expression of ING4 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:159,528,183...159,536,762
Ensembl chr 4:157,841,951...157,850,265
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
pinostrobin results in increased expression of INHBA mRNA |
CTD |
PMID:37777166 |
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Ino80 |
INO80 complex ATPase subunit |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of INO80 protein |
CTD |
PMID:37164308 |
|
NCBI chr 3:126,822,280...126,919,532
Ensembl chr 3:106,368,455...106,467,911
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression |
ISO |
pinostrobin results in increased expression of IRF7 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
ISO |
pinostrobin results in increased expression of ITGAM mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
increases expression |
ISO |
pinostrobin results in increased expression of ITPK1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 6:127,475,589...127,609,320
Ensembl chr 6:121,710,755...121,844,107
|
|
G |
Kdm2b |
lysine demethylase 2B |
increases expression |
ISO |
pinostrobin results in increased expression of KDM2B mRNA |
CTD |
PMID:37777166 |
|
NCBI chr12:39,224,422...39,362,126
Ensembl chr12:33,574,657...33,701,355
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in increased expression of LCN2 protein] |
CTD |
PMID:37342552 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lgals2 |
galectin 2 |
increases expression |
ISO |
pinostrobin results in increased expression of LGALS2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:112,283,630...112,290,228
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Methotrexate results in increased expression of LHB protein] |
CTD |
PMID:37866152 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Madd |
MAP-kinase activating death domain |
increases expression |
ISO |
pinostrobin results in increased expression of MADD mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:97,570,141...97,613,688
Ensembl chr 3:77,114,314...77,157,701
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
pinostrobin results in decreased expression of MCL1 mRNA |
CTD |
PMID:37164308 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression |
ISO |
pinostrobin results in increased expression of MEF2A mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
increases expression |
ISO |
pinostrobin results in increased expression of MEF2D mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 2:175,904,332...175,933,451
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Mir410 |
microRNA 410 |
decreases expression multiple interactions |
ISO |
pinostrobin results in decreased expression of MIR410 mRNA [MIR410 mRNA co-treated with pinostrobin] results in increased expression of CASP3 mRNA; [MIR410 mRNA co-treated with pinostrobin] results in increased expression of CASP3 protein; pinostrobin inhibits the reaction [MIR410 mRNA results in decreased expression of SFRP5 mRNA]; pinostrobin inhibits the reaction [MIR410 mRNA results in decreased expression of SFRP5 protein]; pinostrobin inhibits the reaction [MIR410 mRNA results in increased expression of CTNNB1 mRNA]; pinostrobin inhibits the reaction [MIR410 mRNA results in increased expression of CTNNB1 protein] |
CTD |
PMID:37164308 |
|
NCBI chr 6:134,579,763...134,579,838
Ensembl chr 6:128,758,354...128,758,434
|
|
G |
Mrpl1 |
mitochondrial ribosomal protein L1 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of MRPL1 protein |
CTD |
PMID:37164308 |
|
NCBI chr14:13,604,498...13,663,633
Ensembl chr14:13,300,522...13,359,721
|
|
G |
Mt3 |
metallothionein 3 |
increases expression |
ISO |
pinostrobin results in increased expression of MT3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr19:10,854,676...10,856,080
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mutyh |
mutY DNA glycosylase |
increases expression |
ISO |
pinostrobin results in increased expression of MUTYH mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 5:135,510,666...135,522,777
Ensembl chr 5:130,274,122...130,286,146
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
increases expression |
ISO |
pinostrobin results in increased expression of NAIP mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
ISO |
pinostrobin results in increased expression of NINJ1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr17:15,659,208...15,668,115
Ensembl chr17:15,452,813...15,461,704
|
|
G |
Nisch |
nischarin |
increases expression |
ISO |
pinostrobin results in increased expression of NISCH mRNA |
CTD |
PMID:37777166 |
|
NCBI chr16:6,370,809...6,407,104
Ensembl chr16:6,364,374...6,400,668
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
increases expression |
ISO |
pinostrobin results in increased expression of NLRP1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:56,277,134...56,332,229
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in increased expression of NOS2 protein]; pinostrobin inhibits the reaction [Methotrexate results in increased activity of NOS2 protein] |
CTD |
PMID:37342552 PMID:37866152 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
pinostrobin results in increased expression of NOS3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
ISO |
pinostrobin results in increased expression of NR4A1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Ntsr1 |
neurotensin receptor 1 |
increases expression |
ISO |
pinostrobin results in increased expression of NTSR1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:187,983,778...188,033,934
Ensembl chr 3:167,606,215...167,656,377
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
increases expression |
ISO |
pinostrobin results in increased expression of P2RX1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
pinostrobin results in increased expression of P2RX7 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Pde1b |
phosphodiesterase 1B |
increases expression |
ISO |
pinostrobin results in increased expression of PDE1B mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:136,505,834...136,533,034
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Peli3 |
pellino E3 ubiquitin protein ligase family member 3 |
increases expression |
ISO |
pinostrobin results in increased expression of PELI3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:211,659,416...211,672,280
Ensembl chr 1:202,232,228...202,242,857
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
pinostrobin results in increased expression of PHLDA3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr13:49,745,003...49,748,088
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Pim2 |
Pim-2 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
pinostrobin results in increased expression of PIM2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr X:17,289,509...17,294,778
Ensembl chr X:14,617,582...14,622,851
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
increases expression |
ISO |
pinostrobin results in increased expression of PLAUR mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pld1 |
phospholipase D1 |
increases expression |
ISO |
pinostrobin results in increased expression of PLD1 protein |
CTD |
PMID:37164308 |
|
NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Plec |
plectin |
decreases expression |
ISO |
pinostrobin results in decreased expression of PLEC protein |
CTD |
PMID:37164308 |
|
NCBI chr 7:109,768,447...109,829,798
Ensembl chr 7:107,887,764...107,945,467
|
|
G |
Plxnd1 |
plexin D1 |
increases expression |
ISO |
pinostrobin results in increased expression of PLXND1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:150,675,377...150,715,706
Ensembl chr 4:149,002,784...149,043,244
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO |
pinostrobin results in increased expression of PMP22 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:48,294,932...48,324,941
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pou3f3 |
POU class 3 homeobox 3 |
increases expression |
ISO |
pinostrobin results in increased expression of POU3F3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 9:52,438,026...52,441,152
Ensembl chr 9:44,945,872...44,948,992
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
ISO |
pinostrobin results in increased expression of PPARA mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Cadmium results in increased expression of PTGS2 protein] |
CTD |
PMID:37342552 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases expression |
ISO |
pinostrobin results in increased expression of PTK2B mRNA |
CTD |
PMID:37777166 |
|
NCBI chr15:44,536,275...44,656,754
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Qars1 |
glutaminyl-tRNA synthetase 1 |
increases expression |
ISO |
pinostrobin results in increased expression of QARS1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 8:118,086,243...118,094,274
Ensembl chr 8:109,207,705...109,215,739
|
|
G |
Ret |
ret proto-oncogene |
increases expression |
ISO |
pinostrobin results in increased expression of RET mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rnf130 |
ring finger protein 130 |
increases expression |
ISO |
pinostrobin results in increased expression of RNF130 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:34,843,920...34,957,130
Ensembl chr10:34,342,830...34,456,062
|
|
G |
Rnf216 |
ring finger protein 216 |
increases expression |
ISO |
pinostrobin results in increased expression of RNF216 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr12:16,568,327...16,689,868
Ensembl chr12:11,454,797...11,576,304
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
pinostrobin results in increased expression of HLA-F mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:3,407,880...3,484,130
|
|
G |
Rtkn |
rhotekin |
increases expression |
ISO |
pinostrobin results in increased expression of RTKN mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:117,198,496...117,215,660
Ensembl chr 4:115,640,774...115,657,952
|
|
G |
Scfd2 |
sec1 family domain containing 2 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of SCFD2 protein |
CTD |
PMID:37164308 |
|
NCBI chr14:34,037,392...34,369,423
Ensembl chr14:33,683,273...34,008,213
|
|
G |
Scn2a |
sodium voltage-gated channel alpha subunit 2 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of SCN2A protein |
CTD |
PMID:37164308 |
|
NCBI chr 3:70,710,862...70,845,569
Ensembl chr 3:50,302,877...50,437,214
|
|
G |
Scx |
scleraxis bHLH transcription factor |
increases expression |
ISO |
pinostrobin results in increased expression of SCX mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:110,056,897...110,059,283
Ensembl chr 7:108,176,608...108,178,626
|
|
G |
Selenos |
selenoprotein S |
increases expression |
ISO |
pinostrobin results in increased expression of SELENOS mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:129,070,240...129,080,007
Ensembl chr 1:119,659,751...119,669,833
|
|
G |
Serpinf1 |
serpin family F member 1 |
increases expression |
ISO |
pinostrobin results in increased expression of SERPINF1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sfrp5 |
secreted frizzled-related protein 5 |
multiple interactions increases phosphorylation increases expression |
ISO |
pinostrobin inhibits the reaction [MIR410 mRNA results in decreased expression of SFRP5 mRNA]; pinostrobin inhibits the reaction [MIR410 mRNA results in decreased expression of SFRP5 protein] pinostrobin results in increased phosphorylation of SFRP5 protein pinostrobin results in increased expression of SFRP5 mRNA; pinostrobin results in increased expression of SFRP5 protein |
CTD |
PMID:37164308 |
|
NCBI chr 1:250,956,050...250,960,512
Ensembl chr 1:241,006,762...241,011,224
|
|
G |
Sharpin |
SHANK-associated RH domain interactor |
increases expression |
ISO |
pinostrobin results in increased expression of SHARPIN mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 7:109,951,336...109,955,552
Ensembl chr 7:108,070,687...108,074,955
|
|
G |
Shisa5 |
shisa family member 5 |
increases expression |
ISO |
pinostrobin results in increased expression of SHISA5 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 8:118,569,975...118,584,880
Ensembl chr 8:109,691,522...109,706,408
|
|
G |
Slc10a5 |
solute carrier family 10, member 5 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of SLC10A5 protein |
CTD |
PMID:37164308 |
|
NCBI chr 2:93,364,959...93,366,263
Ensembl chr 2:91,444,454...91,489,651
|
|
G |
Slc25a5-ps11 |
solute carrier family 25 member 5, pseudogene 11 |
increases expression |
ISO |
pinostrobin results in increased expression of SLC25A6 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr18:70,846,358...70,847,597
Ensembl chr18:68,571,300...68,572,199
|
|
G |
Slc46a2 |
solute carrier family 46, member 2 |
increases expression |
ISO |
pinostrobin results in increased expression of SLC46A2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 5:79,594,003...79,603,074
Ensembl chr 5:74,800,226...74,808,128
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
pinostrobin results in increased expression of SLC7A11 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slco5a1 |
solute carrier organic anion transporter family, member 5A1 |
increases expression |
ISO |
pinostrobin results in increased expression of SLCO5A1 protein |
CTD |
PMID:37164308 |
|
NCBI chr 5:11,012,001...11,141,180
Ensembl chr 5:6,228,973...6,352,913
|
|
G |
Smad3 |
SMAD family member 3 |
increases expression |
ISO |
pinostrobin results in increased expression of SMAD3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smim7 |
small integral membrane protein 7 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of SMIM7 protein |
CTD |
PMID:37164308 |
|
NCBI chr16:17,308,466...17,312,384
Ensembl chr16:17,273,258...17,278,336
|
|
G |
Stap2 |
signal transducing adaptor family member 2 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of STAP2 protein |
CTD |
PMID:37164308 |
|
NCBI chr 9:915,546...924,604
Ensembl chr 9:828,372...837,219
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
ISO |
pinostrobin results in increased expression of STAR mRNA |
CTD |
PMID:37777166 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
increases expression |
ISO |
pinostrobin results in increased expression of STXBP1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:36,474,428...36,536,120
Ensembl chr 3:16,076,391...16,138,369
|
|
G |
Sycp2l |
synaptonemal complex protein 2-like |
increases expression |
ISO |
pinostrobin results in increased expression of SYCP2L mRNA |
CTD |
PMID:37777166 |
|
NCBI chr17:23,798,424...23,851,017
Ensembl chr17:23,592,899...23,648,306
|
|
G |
Taf10 |
TATA-box binding protein associated factor 10 |
increases expression |
ISO |
pinostrobin results in increased expression of TAF10 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:169,506,940...169,508,234
Ensembl chr 1:160,095,108...160,096,376
|
|
G |
Tcirg1 |
T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3 |
increases expression |
ISO |
pinostrobin results in increased expression of TCIRG1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:210,556,270...210,568,021
Ensembl chr 1:201,127,034...201,138,742
|
|
G |
Tmem109 |
transmembrane protein 109 |
increases expression |
ISO |
pinostrobin results in increased expression of TMEM109 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 1:216,944,516...216,955,091
Ensembl chr 1:207,519,624...207,530,215
|
|
G |
Tmem39a |
transmembrane protein 39a |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of TMEM39A protein |
CTD |
PMID:37164308 |
|
NCBI chr11:75,666,154...75,695,486
Ensembl chr11:62,160,631...62,189,964
|
|
G |
Tmem79 |
transmembrane protein 79 |
increases expression |
ISO |
pinostrobin results in increased expression of TMEM79 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 2:176,096,092...176,100,996
Ensembl chr 2:173,798,267...173,803,046
|
|
G |
Tmprss4 |
transmembrane serine protease 4 |
increases phosphorylation |
ISO |
pinostrobin results in increased phosphorylation of TMPRSS4 protein |
CTD |
PMID:37164308 |
|
NCBI chr 8:54,372,805...54,405,157
Ensembl chr 8:45,476,053...45,508,409
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Azoxymethane results in increased expression of TNF protein]; pinostrobin inhibits the reaction [Cadmium results in increased expression of TNF protein]; pinostrobin inhibits the reaction [Methotrexate results in increased expression of TNF protein] |
CTD |
PMID:37342552 PMID:37866152 PMID:38078205 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions |
EXP |
pinostrobin inhibits the reaction [Methotrexate results in increased expression of TNFRSF11A protein] |
CTD |
PMID:37866152 |
|
NCBI chr13:22,442,930...22,501,257
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfsf14 |
TNF superfamily member 14 |
increases expression |
ISO |
pinostrobin results in increased expression of TNFSF14 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 9:2,155,270...2,160,100
Ensembl chr 9:2,069,104...2,073,216
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
pinostrobin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
pinostrobin results in increased expression of TP53 mRNA |
CTD |
PMID:37208425 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
increases expression |
ISO |
pinostrobin results in increased expression of TRAP1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:11,971,259...12,005,306
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
pinostrobin results in increased expression of TRIB3 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
increases expression |
ISO |
pinostrobin results in increased expression of TRPM2 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases expression |
ISO |
pinostrobin results in increased expression of TRPV1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
pinostrobin results in increased expression of VEGFA mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
pinostrobin results in increased expression of XBP1 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Zfp746 |
zinc finger protein 746 |
increases expression |
ISO |
pinostrobin results in increased expression of ZNF746 mRNA |
CTD |
PMID:37777166 |
|
NCBI chr 4:78,385,945...78,410,240
Ensembl chr 4:77,055,008...77,078,897
|
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
sakuranetin results in decreased activity of CYP19A1 protein |
CTD |
PMID:38403145 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
sanggenon G results in decreased activity of PTPN1 protein |
CTD |
PMID:16356713 |
|
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504
|
|
|
G |
Il4 |
interleukin 4 |
decreases secretion |
ISO |
silidianin results in decreased secretion of IL4 protein |
CTD |
PMID:32284261 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
ISO |
silidianin results in decreased secretion of IL5 protein silidianin results in decreased expression of IL5 mRNA |
CTD |
PMID:32284261 |
|
NCBI chr10:38,375,132...38,378,003
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Pf4 |
platelet factor 4 |
multiple interactions |
ISO |
silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein] |
CTD |
PMID:29439388 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation |
ISO |
silidianin results in increased phosphorylation of VASP protein |
CTD |
PMID:29439388 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein] 8-prenylnaringenin results in increased expression of ALPL mRNA 8-prenylnaringenin results in increased activity of ALPL protein |
CTD |
PMID:12650720 PMID:16019205 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of C3 mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; 8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased reduction of 2,3-hexanedione] |
CTD |
PMID:30849340 |
|
NCBI chr11:46,346,405...46,348,815
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of CGA mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Csn2 |
casein beta |
increases expression multiple interactions |
EXP |
8-prenylnaringenin results in increased expression of CSN2 mRNA Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of CSN2 mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr14:20,601,824...20,609,061
Ensembl chr14:20,322,581...20,329,817
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO |
8-prenylnaringenin results in decreased activity of CYP1A1 protein 8-prenylnaringenin results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:19770484 PMID:32986415 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
8-prenylnaringenin results in decreased activity of CYP1A2 protein 8-prenylnaringenin results in increased expression of CYP1A2 mRNA |
CTD |
PMID:15672752 PMID:19770484 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
8-prenylnaringenin results in decreased activity of CYP3A4 protein |
CTD |
PMID:19770484 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression increases expression increases activity |
ISO EXP |
8-prenylnaringenin analog binds to and results in increased activity of ESR1 protein; 8-prenylnaringenin binds to and results in increased activity of ESR1 protein; [8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein]; Fulvestrant inhibits the reaction [[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein] 8-prenylnaringenin results in increased expression of ESR1 mRNA [Fulvestrant co-treated with 8-prenylnaringenin] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein] 8-prenylnaringenin results in increased activity of ESR1 protein |
CTD |
PMID:12623674 PMID:12650720 PMID:15876408 PMID:16076101 PMID:17149865 PMID:17716812 PMID:32986415 PMID:34848279 More...
|
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression multiple interactions increases expression increases activity |
EXP ISO |
8-prenylnaringenin results in decreased expression of ESR2 mRNA [Fulvestrant co-treated with 8-prenylnaringenin] results in increased expression of ESR2 mRNA 8-prenylnaringenin results in increased expression of ESR2 mRNA 8-prenylnaringenin analog binds to and results in decreased activity of ESR2 protein; 8-prenylnaringenin binds to and results in increased activity of ESR2 protein 8-prenylnaringenin results in increased activity of ESR2 protein |
CTD |
PMID:16076101 PMID:16522720 PMID:17149865 PMID:17716812 PMID:34848279 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of FSHB protein |
CTD |
PMID:16522720 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gnrhr |
gonadotropin releasing hormone receptor |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of GNRHR mRNA |
CTD |
PMID:16522720 |
|
NCBI chr14:22,211,666...22,229,654
Ensembl chr14:21,856,871...21,874,861
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
[Fulvestrant co-treated with 8-prenylnaringenin] results in decreased expression of IGF1 mRNA |
CTD |
PMID:34848279 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of IGF1R mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
8-prenylnaringenin results in decreased expression of IL6 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif11 |
kinesin family member 11 |
multiple interactions increases expression |
EXP |
Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of KIF11 mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr 1:244,494,916...244,589,250
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif18a |
kinesin family member 18A |
increases expression multiple interactions |
EXP |
8-prenylnaringenin results in increased expression of KIF18A mRNA Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of KIF18A mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:95,764,388...95,824,582
|
|
G |
Kif2c |
kinesin family member 2C |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of KIF2C mRNA |
CTD |
PMID:26372666 |
|
NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of LHB mRNA; 8-prenylnaringenin results in decreased expression of LHB protein |
CTD |
PMID:16522720 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of MKI67 mRNA |
CTD |
PMID:26372666 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO EXP |
8-prenylnaringenin results in increased expression of PGR mRNA Fulvestrant inhibits the reaction [8-prenylnaringenin results in increased expression of PGR mRNA] 8-prenylnaringenin results in increased expression of PGR mRNA; 8-prenylnaringenin results in increased expression of PGR protein |
CTD |
PMID:16076101 PMID:16522720 PMID:16837889 PMID:34848279 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prl |
prolactin |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of PRL protein |
CTD |
PMID:16522720 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
8-prenylnaringenin results in increased expression of TFF1 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
8-prenylnaringenin results in increased expression of VWF mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539
|
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
sophoranone results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
sophoranone results in decreased activity of CYP2D6 protein |
CTD |
PMID:29753067 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
sophoranone results in decreased activity of CYP3A4 protein |
CTD |
PMID:29753067 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|